[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1093
1. Kim SH, Seo BK, Lee J, Kim SJ, Cho KR, Lee KY, Je BK, Kim HY, Kim YS, Lee JH: Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer. Acta Oncol; 2008;47(8):1531-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer.
  • BACKGROUND AND PURPOSE: Ultrasound has been used successfully to differentiate benign and malignant breast lesions.
  • The aim of this study was to investigate the correlation between ultrasound and prognostic indicators in breast cancer such as histological type, tumor grade, and biological markers.
  • MATERIALS AND METHODS: Ultrasound findings (shape, margin, orientation, boundary, echo pattern, posterior acoustic feature, and presence of calcifications) of 458 breast cancers were analyzed and correlated with the tumor type, tumor grade, and biological markers by univariate and multivariate logistic regression analyses.
  • CONCLUSION: Ultrasound pattern is correlated with tumor type, tumor grade, and biological markers in breast cancers and it may be useful for prediction of prognosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / ultrastructure. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Intraductal, Noninfiltrating / ultrastructure. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Carcinoma, Lobular / ultrastructure. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607848.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


2. Sakamoto N, Tozaki M, Higa K, Tsunoda Y, Ogawa T, Abe S, Ozaki S, Sakamoto M, Tsuruhara T, Kawano N, Suzuki T, Yamashiro N, Fukuma E: Categorization of non-mass-like breast lesions detected by MRI. Breast Cancer; 2008;15(3):241-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Categorization of non-mass-like breast lesions detected by MRI.
  • BACKGROUND: Breast MR imaging has emerged as a highly sensitive modality for the imaging of breast tumors.
  • The purpose of this study was to analyze the features of non-mass-like breast lesions detected by MRI, and to establish a standardized method of interpretation to allow categorization of these lesions.
  • The presence of a ductal pattern was assessed in the enhancing lesions after the tumor distribution had been decided.
  • All lesions showing multiquadrant distribution, linear-nonspecific lesion, non-branching pattern with homogeneous and stippled internal architectures, and heterogeneous lesion without clustered ring enhancement were diagnosed as benign.
  • CONCLUSION: Non-mass-like breast lesions detected on MRI showing a clustered ring enhancement, a branching-ductal pattern, and clumped architecture should be evaluated further by biopsy (category 4), while lesions not showing these characteristics may be observed without unnecessary intervention (category 3a).
  • [MeSH-major] Breast Diseases / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Interpretation, Computer-Assisted. Mammography. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18224381.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Hsiao YH, Huang YL, Liang WM, Lin C, Kuo SJ, Chen DR: Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging. Ultrasound Med Biol; 2009 Mar;35(3):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses: harmonic versus nonharmonic 3D power Doppler imaging.
  • The aim of this study was to compare the diagnostic performance of nonharmonic ultrasound (US) and tissue harmonic imaging (THI) using three-dimensional (3D) power Doppler sonographic technique to classify benign and malignant breast tumors by vascularization.
  • All subjects with one or more breast masses were studied with 3D power Doppler US nonharmonic and harmonic technologies.
  • A total of 97 benign and 86 pathologically proven malignant breast tumor images were analyzed.
  • Three histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), on both nonharmonic and harmonic images were calculated for the intratumor and for shells with an outside thickness of 3 mm surrounding the breast lesion.
  • A multilayer perception (MLP) neural network classifier used the vascularity indices to determine whether the breast tumors are benign or malignant.
  • ROC curve analysis used overall age, volume, VI, FI and VFI for both intratumor and shells with an outside thickness of 3 mm surrounding the breast lesions in nonharmonic US and THI.
  • In conclusion, the performance of 3D power Doppler US with respect to the characterization of solid breast masses as benign or malignant was not significantly improved with tissue harmonic imaging.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neovascularization, Pathologic / ultrasonography. Neural Networks (Computer). Ultrasonography, Doppler / methods. Ultrasonography, Mammary / methods. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041173.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene; 2008 Dec 11;27(58):7274-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder.
  • The mechanism by which EZH2 mediates tumor aggressiveness is unclear.
  • Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Dec;23(4):474-8 [10581039.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] Nat Cell Biol. 2002 Mar;4(3):222-31 [11836526.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):151-61 [12020801.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Science. 2003 Apr 4;300(5616):131-5 [12649488.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):306-19 [14673164.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Br J Cancer. 1982 Mar;45(3):361-6 [7073932.001]
  • [Cites] Cell. 1983 Sep;34(2):455-66 [6352050.001]
  • [Cites] Surg Clin North Am. 1990 Aug;70(4):937-62 [2371651.001]
  • [Cites] J Cell Biol. 1991 Apr;113(1):173-85 [2007622.001]
  • [Cites] J Pathol. 1993 Feb;169(2):245-50 [8383197.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1696-701 [8453644.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3618-23 [8339268.001]
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3929-33 [7518346.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):614-6 [7880746.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1319-26 [7478552.001]
  • [Cites] Virchows Arch. 1995;427(3):259-63 [7496594.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):374-7 [9291424.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9656-64 [10092652.001]
  • [Cites] Semin Cell Dev Biol. 1999 Apr;10(2):227-35 [10441076.001]
  • [Cites] Biochim Biophys Acta. 1999 Oct 6;1447(1):1-16 [10500238.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8629-38 [15467754.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):389-402 [15601859.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):736-43 [15720799.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1754-8 [15856046.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3139-43 [15918205.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):349-53 [16012774.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31470-7 [16009709.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):794-5 [16482140.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1123-36 [16618801.001]
  • [Cites] Nature. 2006 May 18;441(7091):349-53 [16625203.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):694-9 [16628213.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):846-56 [17060944.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3199-214 [17158740.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1050-63 [17437993.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4590-5 [17237810.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Cancer Sci. 2008 Apr;99(4):738-46 [18377425.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):741-50 [18488029.001]
  • (PMID = 18806826.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129565-01A1; United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / K99 CA129565-01A1; United States / NCI NIH HHS / CA / CA111275-04; United States / NCI NIH HHS / CA / P50 CA69568; United States / NCI NIH HHS / CA / P50 CA069568-06A10016; United States / NCI NIH HHS / CA / CA069568-110020; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / CA069568-06A10016; United States / NCI NIH HHS / CA / K99 CA129565; United States / NCI NIH HHS / CA / U01 CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275; United States / NCI NIH HHS / CA / R01 CA097063; United States / NCI NIH HHS / CA / R01 CA97063
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Histones; 0 / Polycomb-Group Proteins; 0 / Repressor Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2
  • [Other-IDs] NLM/ NIHMS104449; NLM/ PMC2690514
  •  go-up   go-down


5. Sando N, Oka K, Moriya T, Saito H, Nagakura S, Mori N, Suzuki T, Ueki H, Ohtani H: Osteosarcoma arising in the breast. APMIS; 2006 Jul-Aug;114(7-8):581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma arising in the breast.
  • We report on a 49-year-old woman with osteosarcoma arising in the breast.
  • She had undergone two consecutive excision biopsies for right breast tumors at ages 40 and 42 years.
  • The tumors were diagnosed as a fibroadenoma and a benign phyllodes tumor, respectively.
  • At age 46 years, she noticed a gradually enlarging mass in the same breast.
  • The tumor occupied the entire breast and measured 12x9x8.5 cm.
  • The tumor cells were spindle-shaped and pleomorphic, with large, irregular nuclei and distinct nucleoli.
  • Many tumor cells had characteristics of osteoblastic and chondroblastic elements producing osteoid, osseous, and cartilaginous intracellular substances.
  • Tumor cells expressed vimentin, osteopontin, vascular endothelial growth factor, CD10, and alkaline phosphatase, but did not express keratin.
  • [MeSH-major] Breast Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16907866.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


6. Chan E, Nimnual AS: Deregulation of the cell cycle by breast tumor kinase (Brk). Int J Cancer; 2010 Dec 1;127(11):2723-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of the cell cycle by breast tumor kinase (Brk).
  • Brk is a cytoplasmic nonreceptor tyrosine kinase that is overexpressed in breast tumors but undetectable in normal or benign mammary tissues.
  • Brk promotes proliferation of human mammary epithelial cells and tumor growth in a mouse model, but the role of Brk in cell cycle regulation is not known.
  • Deregulation of the cell cycle is a key event in neoplasia, and thus, the mechanism presented here likely contributes to breast cancer development.
  • [MeSH-major] Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Cell Cycle / physiology. Neoplasm Proteins / metabolism. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Cell Growth Processes / physiology. Cell Line, Tumor. Cell Nucleus / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Down-Regulation. Female. Forkhead Transcription Factors / antagonists & inhibitors. Forkhead Transcription Factors / genetics. Forkhead Transcription Factors / metabolism. G1 Phase / physiology. Humans. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. S Phase / physiology. Transfection

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162673.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / PTK6 protein, human
  •  go-up   go-down


7. Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM: Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients. Tumori; 2006 Nov-Dec;92(6):524-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients.
  • AIMS AND BACKGROUND: This study aims to detect the expression of E-selectin in tissue and the serum level of its soluble form in patients with primary breast cancer and benign breast tumors and to correlate the results with the clinicopathological data of the subjects.
  • Group A comprised 30 patients with primary breast cancer, group B 9 patients with benign breast tumors, and group C 11 healthy control women undergoing reduction mammoplasty.
  • E-selectin gene expression was investigated in breast tissues by PCR techniques and soluble E-selectin was measured in sera by ELISA.
  • It was expressed in 61.5% of patients with grade 2 breast cancer and in 82.4% of patients with grade 3 breast cancer.
  • It was detected in 81.8% of patients with node-positive primary breast cancer and in 50% of patients with node-negative cancer.
  • E-selectin was found on the membranes of peritumoral endothelial cells while it was not found on breast epithelial cells.
  • They increased significantly with increasing breast cancer stage (P < 0.001) and were significantly higher in patients with lymph node involvement than in patients without node involvement (P < 0.001).
  • CONCLUSIONS: The studied marker showed associations with established prognostic parameters such as lymph node involvement and histological tumor grade.
  • E-selectin can be regarded as a promising strategy in improving tumor therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. E-Selectin / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Diseases / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260494.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E-Selectin
  •  go-up   go-down


8. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration biopsy (FNAB) is useful for initial evaluation; nevertheless, malignancy is uncertain when follicular neoplasm is reported.
  • METHODS: We analyzed the clinical files of consecutive patients with cytological diagnoses of follicular neoplasm.
  • Definitive report showed 45 benign (60%) and 30 malignant (40%) cases.
  • Benign cases included 29 goiters, 11 follicular adenomas, and 5 cases of thyroiditis.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • Tumor size of benign lesions was 3.43 ± 2.04 cm, and 4.67 ± 2.78 (p = 0.049) for malignant lesions.
  • Age was 46.95 ± 15.39 years for benign lesions and 48.67 ± 17.28 for malignant lesions (p = 0.66).
  • [MeSH-major] Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


9. Lv H, Pan G, Zheng G, Wu X, Ren H, Liu Y, Wen J: Expression and functions of the repressor element 1 (RE-1)-silencing transcription factor (REST) in breast cancer. J Cell Biochem; 2010 Jul 1;110(4):968-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and functions of the repressor element 1 (RE-1)-silencing transcription factor (REST) in breast cancer.
  • Recently, the tumor-suppressor function of REST is finally proved.
  • However, the expression profile and function of REST in breast cancer are not very clear.
  • In this study, the expression of REST was detected in breast cancer tissue by immunohistochemistry.
  • The results showed that REST expression was significantly lower in breast cancer samples compared to normal and benign breast samples (P < 0.05).
  • Furthermore, the shRNA approach was used to investigate the function of REST in human breast cancer cells.
  • Knocking down REST expression by shRNA in the human breast cancer MCF-7 cells resulted in an increase in cell proliferation, suppression in apoptosis, and reduced sensitivity to anticancer drug with a concurrent significantly up-regulated expression of Bcl-2.
  • These data implied a significant role of REST in breast cancer.
  • The reduced expression of REST might contribute to the breast cancer pathogenesis.
  • [MeSH-major] Breast Neoplasms / genetics. Nerve Tissue Proteins / physiology. Repressor Proteins / physiology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Proliferation. Co-Repressor Proteins. Female. Gene Expression Profiling. Gene Knockdown Techniques. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Cell. Biochem. 110: 968-974, 2010. (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20564196.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Co-Repressor Proteins; 0 / Nerve Tissue Proteins; 0 / RCOR1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


10. Rissanen T, Reinikainen H, Apaja-Sarkkinen M: Breast sonography in localizing the cause of nipple discharge: comparison with galactography in 52 patients. J Ultrasound Med; 2007 Aug;26(8):1031-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast sonography in localizing the cause of nipple discharge: comparison with galactography in 52 patients.
  • OBJECTIVE: The purpose of this study was to evaluate breast sonography in localizing abnormalities in the discharging duct in patients with spontaneous nipple discharge.
  • METHODS: Fifty-two patients with unilateral bloody or serous nipple discharge and normal findings on palpation and mammography underwent breast sonography before surgical duct excision.
  • RESULTS: The final diagnosis was benign in 47 cases (90%) and malignant in 5 cases (10%).
  • Sonography visualized an echogenic intraductal tumor in 36 (69%) of 52 cases, dilated duct(s) without an intraductal tumor in 6 cases (12%), and no abnormality in 10 cases (19%).
  • Eighty percent of papillomatous lesions, 58% of other benign lesions, and 20% of malignant lesions were sonographically positive.
  • [MeSH-major] Breast Diseases / ultrasonography. Nipples / secretion. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Breast Neoplasms / surgery. Breast Neoplasms / ultrasonography. Contrast Media. Diagnosis, Differential. Exudates and Transudates. Female. Humans. Iohexol / analogs & derivatives. Methylene Blue. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646365.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide; T42P99266K / Methylene Blue
  •  go-up   go-down


11. Shin SJ, Scamman W, Gopalan A, Rosen PP: Mammary presentation of adult-type "juvenile" xanthogranuloma. Am J Surg Pathol; 2005 Jun;29(6):827-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile xanthogranuloma (JXG) is a benign histiocytic disorder of infants and childhood.
  • Herein, we report an exceptional case of adult xanthogranuloma in a 74-year-old woman who presented with ipsilateral breast masses and also found to have prior cutaneous lesions.
  • This is the first reported case of cutaneous and extracutaneous adult JXG where the latter manifested in the breast as a spindle cell xanthogranuloma.
  • In the breast, the morphologic features of JXG evoked several entities in the differential diagnosis, including spindle cell metaplastic carcinoma, inflammatory pseudotumor, fibromatosis, myofibroblastoma, and phyllodes tumor.
  • With the aid of immunohistochemical stains and appropriate clinical history, the correct diagnosis of extracutaneous adult JXG manifesting as a spindle cell xanthogranuloma can be made.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology. Xanthogranuloma, Juvenile / pathology
  • [MeSH-minor] Age Factors. Aged. Biopsy. Female. Humans


12. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Radiation Dosage. Retrospective Studies. Survival Rate


13. Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE, Moroni M: HYOU1/Orp150 expression in breast cancer. Med Sci Monit; 2007 Nov;13(11):BR231-239
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HYOU1/Orp150 expression in breast cancer.
  • Preliminary studies demonstrated increased HYOU1/Orp150 expression in prostate, bladder and invasive breast cancer.
  • This study further evaluates HYOU1/Orp150 expression in different stages of breast cancer such as benign, pre-malignant and malignant lesions, and correlates it with clinical and pathological data.
  • MATERIAL/METHODS: Sixty-six paraffin-embedded breast tissue sections were stained by immunohistochemistry using HYOU1/Orp150 antibody.
  • RESULTS: There was a small but significant increase (P<0.01) in HYOU1/Orp150 expression as the tumor transformed from benign (mean 1.52+/-0.12) to ductal carcinoma in situ (mean 2.05+/-0.14) and invasive carcinoma (mean 2.1+/-0.17).
  • HYOU1/Orp150 was partially lost in the benign tissue adjacent to purely invasive cancer (0.88+/-0.22) and it was less (P=0.046) than what was found in benign only lesions (1.52+/-0.12) or in benign components adjacent to DCIS (1.47+/-0.16).
  • Overexpression of HYOU1/Orp150 was associated with tumor lymph node involvement, presence of lymphovascular invasion, and absence of estrogen receptor expression (P<0.01).
  • CONCLUSIONS: HYOU1/Orp150 is overexpressed in some invasive breast cancers and its overexpression appears to be associated with indicators of poor prognosis.
  • [MeSH-major] Breast Neoplasms / metabolism. Proteins / metabolism
  • [MeSH-minor] Breast Diseases / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Female. HSP70 Heat-Shock Proteins. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies


14. Salhab M, Singh-Ranger G, Mokbel R, Jouhra F, Jiang WG, Mokbel K: Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol; 2007 Oct 1;96(5):424-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer.
  • INTRODUCTION: The cyclooxygenase-2 (COX-2), responsible for the conversion of arachidonic acid into prostaglandin (PG) E2, is known to increase intracellular cAMP and estrogen production in malignant breast tissue.
  • The aromatase enzyme complex is responsible for local production of estrogens in breast cancer.
  • The aim of this study was to examine the relationship between COX-2 and aromatase mRNA expression in human breast cancer.
  • METHODS: A total of 160 breast samples (127 tumor tissues and 33 normal tissues) were analyzed.
  • RESULTS: Levels of expression of COX-2/CK19 of both benign and malignant tissues were positively correlated with aromatase/CK19 transcript levels (correlation coefficient = +0.536, P < 0.0001).
  • CONCLUSION: This study demonstrates a strong positive relationship between COX-2 and aromatase mRNA expression, and lends further support to the hypothesis that COX-2 is an upregulator of aromatase in breast tissue.
  • [MeSH-major] Aromatase / metabolism. Breast Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. RNA, Messenger / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Breast / metabolism. Female. Humans. Keratin-19 / metabolism. Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657731.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-19; 0 / RNA, Messenger; EC 1.14.14.1 / Aromatase; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


15. Makkat S, Luypaert R, Sourbron S, Stadnik T, De Mey J: Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second-bolus T1-DCE data. J Magn Reson Imaging; 2007 Jun;25(6):1159-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second-bolus T1-DCE data.
  • PURPOSE: To test the feasibility of using a second-bolus injection, added to a routine breast MRI examination, to measure regional perfusion and permeability in human breast tumors.
  • MATERIALS AND METHODS: In 30 patients with breast tumors, first a routine whole-breast T1-DCE sequence was applied, and the slice where the lesion enhanced maximally was located.
  • A pixel-by-pixel model-independent deconvolution of the relative signal enhancement was performed to estimate the tumor blood flow (TBF), tumor volume of distribution (TVD), mean transit time (MTT), extraction flow product (EF), and extraction fraction (E).
  • RESULTS: In the malignant tumors, the parametric maps clearly delineated tumors from the breast tissue and enabled visualization of the heterogeneity.
  • The deconvolution analysis provided objective parametric maps of tumor perfusion with a mean TBF (84 +/- 48 mL/100 mL/minute) in malignant tumors in the high range of literature values.
  • CONCLUSION: In terms of these perfusion values, our method appears promising to quantitatively characterize tumor pathophysiology.
  • However, the number of patients was limited, and the separation between malignant and benign groups was not clear-cut.
  • Additional parameters generated through compartment modeling may improve the tumor differentiation.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Feasibility Studies. Female. Humans. Image Processing, Computer-Assisted. Injections. Middle Aged. Regional Blood Flow. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17520720.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


16. Kennedy S, Geradts J, Bydlon T, Brown JQ, Gallagher J, Junker M, Barry W, Ramanujam N, Wilke L: Optical breast cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast. Breast Cancer Res; 2010;12(6):R91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical breast cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast.
  • INTRODUCTION: Residual cancer following breast conserving surgery increases the risk of local recurrence and mortality.
  • Breast tissue is markedly heterogeneous, which makes distinguishing small foci of cancer within the spectrum of normal tissue potentially challenging.
  • Here, we evaluate ex-vivo breast tissue and determine which sources of optical contrast have the potential to detect malignancy at the margins in women of differing breast composition.
  • The diagnostic ability of the optical parameters was affected by distance of tumor from the margin as well as menopausal status.
  • CONCLUSIONS: The data indicate that the ability of an optical parameter to differentiate benign from malignant breast tissues may be dictated by patient demographics.
  • Patient demographics are therefore an important component to incorporate into optical characterization of breast specimens.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lasers Surg Med. 2010 Jan;42(1):15-23 [20077490.001]
  • [Cites] J Surg Res. 2010 May 15;160(2):277-81 [19628225.001]
  • [Cites] Blood. 2010 May 20;115(20):4111-9 [20107229.001]
  • [Cites] Opt Express. 2010 Apr 12;18(8):8058-76 [20588651.001]
  • [Cites] Cancer Res. 2009 Nov 15;69(22):8790-6 [19910294.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):26-40 [10933066.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):383-91 [10989610.001]
  • [Cites] Acad Radiol. 2001 Mar;8(3):211-8 [11249084.001]
  • [Cites] Am J Surg. 2002 Nov;184(5):383-93 [12433599.001]
  • [Cites] J Biomed Opt. 2003 Apr;8(2):223-36 [12683848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12349-54 [14514888.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):230-8 [14715078.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):541-52 [15189092.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):490-3 [2009065.001]
  • [Cites] Cancer J Sci Am. 1997 Sep-Oct;3(5):273-7 [9327150.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] J Am Coll Surg. 2005 Aug;201(2):194-8 [16038815.001]
  • [Cites] J Am Coll Surg. 2005 Dec;201(6):855-61 [16310688.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1062-71 [16512550.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1072-8 [16512551.001]
  • [Cites] Technol Cancer Res Treat. 2006 Aug;5(4):301-9 [16866560.001]
  • [Cites] Lasers Surg Med. 2006 Aug;38(7):714-24 [16799981.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1045-50 [17206481.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1458-71 [17260108.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):467-73 [17826057.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2425-7 [17597344.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2953-60 [17674109.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1297-303 [18259820.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1271-2 [18320287.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024012 [18465975.001]
  • [Cites] J Am Coll Surg. 2008 Jun;206(3):1116-21 [18501808.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):034015 [18601560.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):483-9 [18809049.001]
  • [Cites] Breast J. 2009 Jan-Feb;15(1):34-40 [19141132.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1615-20 [19255332.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2919-26 [19293184.001]
  • [Cites] Curr Opin Biotechnol. 2009 Feb;20(1):119-31 [19268567.001]
  • [Cites] Ann Surg Oncol. 2009 Oct;16(10):2717-30 [19609829.001]
  • [Cites] Am J Surg. 2009 Oct;198(4):566-74 [19800470.001]
  • [Cites] JAMA. 2009 Oct 14;302(14):1551-6 [19826024.001]
  • [Cites] J Biomed Opt. 2009 Sep-Oct;14(5):054023 [19895125.001]
  • (PMID = 21054873.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1R41CA128160-01; United States / NCRR NIH HHS / RR / 1UL1 RR024128-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; 01YAE03M7J / beta Carotene
  • [Other-IDs] NLM/ PMC3046432
  •  go-up   go-down


17. Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C: Cell cycle dysregulation influences survival in high risk breast cancer patients. Cancer Invest; 2008 Aug;26(7):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle dysregulation influences survival in high risk breast cancer patients.
  • Recent immunohistological studies suggested that dysregulation of cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), and p27(kip1) are of prognostic value in patients with breast cancer.
  • Our study represents the first comprehensive immunohistochemical cell cycle marker analysis for cdc25A, cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), p27(kip1), and pRb in tumor tissue and adjacent benign breast tissue from 69 primarily untreated breast cancer patients.
  • RESULTS: Sixty-nine patients with untreated, invasive breast cancer (n = 69) were divided into a low/ intermediate and a high risk group according to the St. Gallen 2005 consensus conference.
  • A subgroup of high risk breast cancer patients characterized in addition by overexpression of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) experienced a shortened mean survival of 222.03, 235.71, 257.25, 239.18, and 261.94 weeks, respectively.
  • Regarding benign breast tissue adjacent to breast cancer tissue, 59.4% of the patients investigated overexpressed cdc25A, 23.2% overexpressed pRb, and 63.2% exerted dysregulation of p27(kip1) while they proved to be negative for immunohistochemical staining regarding all other markers tested.
  • CONCLUSION: The immunohistological analyses of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) have the potential for further refining the risk assessment in patients with untreated breast cancer who belong to the high risk category defined according to the St. Gallen 2005 consensus conference.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Breast Neoplasms / mortality. Cell Cycle. Cell Cycle Proteins / analysis. Cell Proliferation
  • [MeSH-minor] Adult. Cyclin A / analysis. Cyclin D. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Kaplan-Meier Estimate. Neoplasm Invasiveness. Proportional Hazards Models. Retinoblastoma Protein / analysis. Retrospective Studies. Risk Assessment. Treatment Outcome. cdc25 Phosphatases / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665474.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  •  go-up   go-down


18. Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S, Van Zee KJ: Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol; 2007 Oct;14(10):2961-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast.
  • BACKGROUND: Phyllodes tumors (PT) are rare fibroepithelial neoplasms of the breast with unpredictable behavior.
  • All available pathology slides (90%) were rereviewed for margins, borders, fibroproliferation in the surrounding breast tissue, stromal pattern, stromal cellularity, frequency of mitoses, and necrosis.
  • RESULTS: All cases occurred in women, with a median age of 42, with 203 originally categorized as benign and 90 as malignant.
  • These patients constituted 71% of the seven patients who had uniformly aggressive pathologic features, including large tumor size (>or=7.0 cm), infiltrative borders, marked stromal overgrowth, marked stromal cellularity, high mitotic count, and necrosis.
  • CONCLUSIONS: Positive margins, fibroproliferation in the surrounding breast tissue, and necrosis are associated with a marked increase in LR rates.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Aged, 80 and over. Breast / pathology. Cell Division / physiology. Child. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Mitosis / physiology. Necrosis. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562113.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Details of MGB expression pattern and its pathologic significance in the female genital tract have not been systematically studied.
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


20. Bewtra C: Fibroadenoma in women in Ghana. Pan Afr Med J; 2009;2:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenoma is the commonest benign tumor of female breast.
  • METHOD: This paper describes the clinicopathologic features of fibroadenoma of breast in African women from central Ghana and compares them to the data from African-American women.
  • RESULTS: Fibroadenomas constituted 47.7% of all palpable breast masses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1422-31 [10778973.001]
  • [Cites] Oncologist. 2006 May;11(5):435-49 [16720843.001]
  • [Cites] Breast J. 2006 Sep-Oct;12(5):451-61 [16958965.001]
  • [Cites] J R Coll Surg Edinb. 1990 Dec;35(6):373-5 [2086798.001]
  • [Cites] Am J Surg. 1979 Jun;137(6):786-9 [453472.001]
  • (PMID = 21532907.001).
  • [ISSN] 1937-8688
  • [Journal-full-title] The Pan African medical journal
  • [ISO-abbreviation] Pan Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC2984278
  •  go-up   go-down


21. Laé M, Vincent-Salomon A, Savignoni A, Huon I, Fréneaux P, Sigal-Zafrani B, Aurias A, Sastre-Garau X, Couturier J: Phyllodes tumors of the breast segregate in two groups according to genetic criteria. Mod Pathol; 2007 Apr;20(4):435-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast segregate in two groups according to genetic criteria.
  • Phyllodes tumors are rare fibroepithelial tumors of the breast.
  • Recurrent chromosome imbalances were observed in 55, 91 and 100% of benign, borderline and malignant phyllodes tumors, respectively.
  • The mean number of chromosome changes was one in benign, six in borderline, and six in malignant phyllodes tumors.
  • Gains of 1q, present in only one of nine benign tumors, were found in 11/21 (51%) borderline or malignant tumors.
  • Conversely, benign tumors could be significantly differentiated from the group composed of borderline and malignant tumors (P<0.01).
  • This study reveals two distinct patterns of genomic imbalance in phyllodes tumors: benign, with none or a few chromosome changes and malignant, with numerous recurrent chromosomal changes, in particular 1q gain and 13q loss.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosome Aberrations. Phyllodes Tumor / genetics
  • [MeSH-minor] Adult. Aged. Cell Nucleus / pathology. Female. Genetic Markers. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Mitosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334353.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


22. Breiting L, Christensen L, Dahlstrøm K, Breiting V, Winther JF: Primary mucinous carcinoma of the skin: a population-based study. Int J Dermatol; 2008 Mar;47(3):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary mucinous carcinoma of the skin (PMCS) is a rare malignant tumor deriving from the sweat glands.
  • It is typically located on the head and is often mistaken for a metastasis from a more common primary tumor of the breast or gastrointestinal tract.
  • CONCLUSION: PMCS is a rare, slow-growing tumor which rarely metastasizes and is associated with low mortality.
  • However, the precise number may be higher, since PMCS is an indolent tumor, which may be mistaken for a benign tumor and thus not always examined histologically.
  • [MeSH-minor] Aged. Aged, 80 and over. Denmark / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Registries. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289323.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


24. Wu HD, Chou SY, Chen DR, Kuo HW: Differentiation of serum levels of trace elements in normal and malignant breast patients. Biol Trace Elem Res; 2006 Oct;113(1):9-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of serum levels of trace elements in normal and malignant breast patients.
  • The objective of this study was to determine which elements in serum best differentiated breast cancer in a case-control study.
  • Concentrations of 13 elements in serum of 68 breast tumor patients (25 malignant and 43 benign) and 26 healthy controls were measured.
  • Sensitivity and specificity of the model were calculated to obtain the optimal cutoff point for discriminating malignant breast cancers vs other individuals (including benign breast disease and normal ones).
  • In conclusion, there was a significant difference in concentrations of all 13 elements in serum between breast cancer patients and controls.
  • A combination among Cd, Mn, Fe, Cr, and Zn might be important to determine a differentiating reference for breast cancers if a long-term followed-up study is to be conducted.
  • [MeSH-major] Breast Neoplasms / blood. Trace Elements / blood
  • [MeSH-minor] Cadmium / blood. Female. Humans. Iron / blood. Logistic Models. Manganese / blood. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114811.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Trace Elements; 00BH33GNGH / Cadmium; 42Z2K6ZL8P / Manganese; E1UOL152H7 / Iron
  •  go-up   go-down


25. Padilla-Rodriguez AL, Padilla-Villalta A, Arandia Y: Synchronous benign and malignant mesenchymal breast tumor. Breast J; 2007 May-Jun;13(3):314-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous benign and malignant mesenchymal breast tumor.
  • [MeSH-major] Breast Neoplasms / pathology. Liposarcoma, Myxoid / pathology. Mesenchymoma / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Breast Diseases / pathology. Female. Fibroma / pathology. Granular Cell Tumor / pathology. Humans. Middle Aged

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461913.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Wood ME, Stanley MA, Crocker AM, Kingsley FS, Leiman G: Ductal lavage of cancerous and unaffected breasts: procedure success rate and cancer detection. Acta Cytol; 2009 Jul-Aug;53(4):410-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate ductal lavage (DL) performance in women with known breast cancer and to assess cell yield from contralateral high-risk breasts.
  • STUDY DESIGN: Women with newly diagnosed breast cancer were offered study participation.
  • Samples were interpreted masked as to which breast was malignant, and the interpretation used a 5-category scheme: insufficient, benign, mildly atypical, markedly atypical or malignant.
  • CONCLUSION: The low sensitivity of DL performed on malignant breasts to identify abnormal cells adds to the growing body of evidence that this is not an effective tool in identifying existing breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis. Therapeutic Irrigation / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Breast / pathology. Female. Humans. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697725.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL: High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol; 2010 Jan;23(1):27-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
  • Papillary lesions of the breast have an uncertain relationship to the histogenesis of breast carcinoma, and are thus diagnostically and managerially challenging.
  • We screened papillary breast neoplasms for activating point mutations in PIK3CA, AKT1, and RAS protein-family members, which are common in invasive ductal carcinomas.
  • DNA extracts were prepared from sections of 89 papillary lesions, including 61 benign papillomas (28 without significant hyperplasia; 33 with moderate to florid hyperplasia), 11 papillomas with atypical ductal hyperplasia, 7 papillomas with carcinoma in situ, and 10 papillary carcinomas.
  • The 10 papillary carcinomas showed an overall lower frequency of mutations, including 1 with an AKT1 mutation (in a tumor arising from a papilloma), 1 with an NRAS gene mutation (Q61H), and 2 with PIK3CA mutations (1 overlapping with the NRAS Q61H).
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Papillary / genetics. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins c-akt / genetics
  • [MeSH-minor] DNA Mutational Analysis. Female. Humans. Mutation. Polymerase Chain Reaction. Prevalence. Signal Transduction / physiology. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization


28. Perkins RS, Sahm K, Marando C, Dickson-Witmer D, Pahnke GR, Mitchell M, Petrelli NJ, Berkowitz IM, Soteropoulos P, Aris VM, Dunn SP, Krueger LJ: Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR. Breast Cancer Res; 2006;8(6):R70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR.
  • This infection is considered benign, even though in limited cases EBV is associated with infectious and neoplastic conditions.
  • Over the past decade, the EBV association with breast cancer has been constantly debated.
  • Adding to this clinical and biological uncertainty, different techniques gave contradictory results for the presence of EBV in breast carcinoma specimens.
  • In this study, minor groove binding (MGB)-TaqMan real time PCR was used to detect the presence of EBV DNA in both peripheral blood and tumor samples of selected patients.
  • METHODS: Peripheral blood and breast carcinoma specimens from 24 patients were collected.
  • RESULTS: Of 24 breast tumor specimens, 11 (46%) were positive for EBV DNA.
  • Of these 11 breast tumor specimens, 7 (64%) were also positive for EBV DNA in the peripheral blood, while 4 (36%) were positive for EBV DNA in the tumor, but negative in the blood.
  • Furthermore, our finding of the presence of EBV in the tumor specimens coupled to the absence of detection of EBV genomic DNA in the peripheral blood is consistent with the epithelial nature of the virus.
  • Because of the low levels of viral DNA in tumor tissue, further studies are needed to assess the biological input of EBV in breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Jan;156(1):1-3 [10623645.001]
  • [Cites] J Virol. 1999 Oct;73(10):8857-66 [10482644.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1849-51 [11078764.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 17;93(2):148-50 [11208885.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):783-90 [11259092.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):571-8 [11485915.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Virology. 2001 Sep 30;288(2):223-35 [11601894.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):759-64 [12118114.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1193-9 [12218080.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R13-7 [12559053.001]
  • [Cites] Nat Med. 2003 Mar;9(3):307-14 [12592401.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2338-43 [12727860.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):113-9 [12838311.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1253-4; author reply 1254-5 [12928356.001]
  • [Cites] J Virol. 2003 Dec;77(24):13267-74 [14645583.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):832-44 [14668814.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1242-7 [14681325.001]
  • [Cites] Eur J Haematol. 2004 Mar;72(3):203-12 [14962239.001]
  • [Cites] Med Hypotheses. 2004;62(3):387-91 [14975509.001]
  • [Cites] J Virol. 2004 May;78(10):5007-14 [15113881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):688-97 [15159298.001]
  • [Cites] J Gen Virol. 2004 Oct;85(Pt 10):2767-78 [15448337.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] Cell. 1988 Jan 15;52(1):51-61 [2830981.001]
  • [Cites] J Clin Pathol. 1994 Jun;47(6):538-40 [8063937.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):39-45 [7805038.001]
  • [Cites] Am J Clin Pathol. 1995 Mar;103(3):308-15 [7872253.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424 [9190379.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):555-8 [9466655.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):53-7 [9500191.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):29-33 [15714061.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):809-14 [15824148.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Virol. 2006 Jan;80(2):845-53 [16378986.001]
  • [Cites] J Virol. 1998 May;72(5):4371-8 [9557727.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Ann Med. 1998 Jun;30(3):249-59 [9677010.001]
  • [Cites] J Virol. 1999 Feb;73(2):1286-92 [9882333.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1349-50 [10451431.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1376-81 [10451442.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 19;92(8):655-6; author reply 656 [10772685.001]
  • (PMID = 17163997.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016472; United States / NCRR NIH HHS / RR / 2 P20 RR016472-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC1797024
  •  go-up   go-down


29. Huang YL, Chen DR, Jiang YR, Kuo SJ, Wu HK, Moon WK: Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound. Ultrasound Obstet Gynecol; 2008 Sep;32(4):565-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided diagnosis using morphological features for classifying breast lesions on ultrasound.
  • OBJECTIVES: To develop and evaluate a computer-aided diagnosis (CAD) system with automatic contouring and morphological analysis to aid in the classification of breast tumors using ultrasound.
  • METHODS: We evaluated 118 breast lesions (34 malignant and 84 benign tumors).
  • Each tumor contour was automatically extracted from the digitized ultrasound image.
  • A support vector machine (SVM) classifier utilized the selected principal vectors to identify the breast tumor as benign or malignant.
  • The classification ability for breast tumors using morphological information was good.
  • CONCLUSIONS: This system differentiates benign from malignant breast tumors well and therefore provides a clinically useful second opinion.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Diagnosis, Computer-Assisted / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Principal Component Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383556.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Balci P, Kabakci N, Topcu I, Canda T, Güray M, Ozfidan S: Breast myxoma: Radiologic and histopathologic features. Breast J; 2007 Jan-Feb;13(1):88-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast myxoma: Radiologic and histopathologic features.
  • Myxomas are benign mesenchymal tumors, which rarely develop in the breast.
  • We present a case of this rare type of breast tumor with sonographic and mammographic findings.
  • [MeSH-major] Breast Neoplasms / diagnosis. Myxoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Mammography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214801.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Nassar A, Cohen C, Cotsonis G, Carlson G: Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome. Breast J; 2008 Mar-Apr;14(2):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome.
  • Intramammary lymph nodes (intraMLNs) have received little attention as potential prognostic indicators for patients with breast carcinoma.
  • Patients with stage I breast carcinoma and positive intraMLN metastases have been reported to have a poorer prognosis compared to patients with similar stage and negative intraMLN metastases.
  • However, the presence of intraMLN metastases does not appear to influence the survival of patients with stage II breast carcinoma.
  • In the current retrospective analysis, we assessed the clinical significance of intraMLNs and evaluated their role in predicting outcome in patients with breast carcinoma.
  • In all, 59 patients (50.8%) were found in association with benign breast conditions and the remaining 57 (49.2%) with primary breast carcinoma.
  • Primary tumor characteristics and axillary lymph node (AxLN) status were recorded.
  • Statistical analysis was performed to detect correlation between intraMLN and tumor characteristics as well as outcome.
  • Univariate analysis revealed that predictors of intraMLN metastases include: tumor size (p = 0.04), tumor grade (p = 0.04), tumor stage (p < 0.001), and AxLN status (p < 0.001).
  • IntraMLN metastasis is a poor prognostic marker but not an independent predictor of poor outcome in patients with breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Nodes. Mammary Glands, Human / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248563.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Liu HM, Wu FL, Chen X, Ye CS, Deng YJ: [Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct;29(10):2115-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of ultrasonographic grading with high-frequency probes in distinguishing breast tumors].
  • OBJECTIVE: To investigate the value of ultrasonographic grading with high-frequency probes in differentiating benign and malignant breast tumors.
  • METHODS: Sixty-four women (mean age 44.5-/+13.7 years) with 79 breast tumors underwent high-frequency ultrasonography to examine the tumor number, size, aspect ratio, shape, boundaries, encapsulation, pseudopod, internal and rear echoes, calcifications, blood perfusion, abnormality lymph nodes in the axilla.
  • RESULTS: Between the 46 women with benign tumors and 18 with malignant tumors, no significant differences were found in the mean tumor number (1.5-/+1.3 vs 1.1-/+0.3, P>0.05) or size (55.0-/+19.2 mm vs 19.8-/+8.3 mm, P>0.05), but the mean age (41.4-/+12.4 years vs 52.4-/+14.1 years) and ultrasonographic grade (2.8-/+2.2 vs 7.3-/+1.7, P<0.05) differed significantly.
  • The ultrasonographic grade of the breast tumors showed an obvious correlation to the nature of the tumors (r=0.695, P<0.001).
  • CONCLUSION: Grading of breast tumors with high-frequency ultrasonography helps evaluate the nature of the tumors, and a higher score suggests increased probability of malignancy.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Grading. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861280.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Korula A, Varghese J, Thomas M, Vyas F, Korula A: Malignant phyllodes tumour with intraductal and invasive carcinoma and lymph node metastasis. Singapore Med J; 2008 Nov;49(11):e318-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phyllodes tumours constitute 2-3 percent of fibroepithelial breast tumours, with a 1-2 percent rate of malignancy.
  • Carcinoma in a phyllodes tumour is distinctly uncommon, but has been known to occur in benign phyllodes tumours.
  • We describe a 51-year-old woman with a malignant phyllodes tumour with foci of intraductal carcinoma within the tumour and adjacent breast tissue.
  • Though the carcinoma was found to be invasive based on the presence of carcinomatous lymph node metastasis, extensive sampling did not yield an invasive component within the breast, probably because of the marked stromal overgrowth of the phyllodes.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma / diagnosis. Carcinoma / pathology. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology
  • [MeSH-minor] Breast / pathology. Breast / surgery. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037540.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


34. Nassar A, Amin MB, Sexton DG, Cohen C: Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, AMACR has been demonstrated to be overexpressed in localized and metastatic prostate cancer and in high-grade prostatic intraepithelial neoplasia but not in normal prostatic glands, suggesting that it may be an important tumor marker.
  • This study examines AMACR expression in a variety of human cancers to assess its viability as a tumor marker in the clinical setting.
  • Cancers studied included breast (94 cases), prostate (38), lung (28), endometrium (27), colon (29), ovary (26), and melanoma (21).
  • A section of prostate cancer and prostatic intraepithelial neoplasia was used as positive control.
  • AMACR protein overexpression was found in several cancers, including prostate (34/38 [89.5%]), colon (13/29 [44.8%]), lung (4/28 [14.3%]), melanoma (2/21 [9.5%]), endometrium (2/27 [7.4%]), and breast (3/94 [3.2%]).
  • AMACR expression was not present in any of the normal tissues nor in benign prostatic tissue associated with prostate carcinomas.
  • This study suggests that AMACR is potentially an important tumor marker, particularly for prostate and colon cancer.
  • It may be a useful adjunct to an immunohistochemical panel employed in the differential diagnosis of colon versus ovarian and breast carcinoma; the latter two infrequently express AMACR.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082251.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


35. Tamura T, Usui S, Murakami S, Arihiro K, Akiyama Y, Naito K, Akiyama M: Biexponential Signal Attenuation Analysis of Diffusion-weighted Imaging of Breast. Magn Reson Med Sci; 2010;9(4):195-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biexponential Signal Attenuation Analysis of Diffusion-weighted Imaging of Breast.
  • In this study, we investigated the clinical utility of DWI for the breast by performing DWI using multiple b-factors on healthy volunteers and clinical subjects, analyzing the signal by fitting it with a biexponential equation, and comparing the fitting parameters of breast lesions.
  • PATIENTS AND METHODS: we investigated 8 healthy women as normal cases and 80 female patients with a total of 100 breast tumors (42 benign, 58 malignant tumors) as clinical cases.
  • Comparison of parameters derived from biexponential fitting demonstrated no significant difference between benign and malignant lesions.
  • For malignant tumor subtype, the fast component fraction of noninvasive ductal carcinoma was statistically greater than that of invasive ductal carcinoma.
  • CONCLUSIONS: although the parameters from biexponential fitting may reflect the character of tumor cellularity, because pathological diagnosis was performed with an emphasis on cell configuration or shape rather than cellularity, it was difficult to distinguish malignant from benign tumors, including many IDPs, or to distinguish tissue types using DWI signal attenuation alone.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Diffusion Magnetic Resonance Imaging / methods. Fibroadenoma / pathology. Papilloma, Intraductal / pathology. Signal Processing, Computer-Assisted
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast / pathology. Breast Diseases / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187689.001).
  • [ISSN] 1880-2206
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Beyrouti MI, Beyrouti R, Khabir A, Ben Amar M, Frikha F, Dhieb N, Damak D, Abid M, Affes N, Boujelben S, Frikha M: [Fibrocystic mastopathy and cancer of the breast. About 111 cases]. Tunis Med; 2006 Oct;84(10):626-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibrocystic mastopathy and cancer of the breast. About 111 cases].
  • [Transliterated title] Mastopathies fibrokystiques et cancers du sein. A propos de 111 cas.
  • METHODS: This work is a retrospective survey of 111 observations of isolated fibrocystic mastopathies or associated to a breast cancer among 542 women admitted for tumor of the breast during one period of 13 active years from 1991 to 2003.
  • The diagnosis has been gotten by anatomo-pathologic exam in 95.5% (106 cas) on the operative piece and 4.5% (5 cas) on a material of biopsy.
  • RESULTS: The fibrocystic mastopathy represented 30% of the set of the benign tumors of the breast.
  • They were associated to a breast cancer in 45 cases (40.5%).
  • The isolated benign fibrocystic mastopathy was observed in 66 cases with a middle age of 37 years, whereas the shapes associated to a breast carcinoma were noted in 45 cases.
  • CONCLUSION: The discovery of a mastopathy must search a luteal failure and risk factors of breast cancer notably a proliferative shape of mastopathy with atypies.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Ductal, Breast. Fibrocystic Breast Disease
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Breast / pathology. Chi-Square Distribution. Data Interpretation, Statistical. Female. Humans. Menopause. Middle Aged. Neoplasm Staging. Parity. Predictive Value of Tests. Pregnancy. Retrospective Studies. Risk. Risk Factors. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17193854.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


37. Aghaei M, Karami-Tehrani F, Salami S, Atri M: Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors. Arch Med Res; 2010 Jan;41(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors.
  • BACKGROUND AND AIMS: The present study was carried out to evaluate the activity of adenosine deaminase (ADA) and its isoenzymes ADA1 and ADA2 activities as a diagnostic tool in patients with benign and malignant breast disease.
  • METHODS: Total ADA, ADA1, and ADA2 activities of serum and tumor were analyzed using 58 subjects including 20 patients with benign breast disease (BBD), 34 patients with primary breast cancer, and 20 patients as normal control subjects.
  • RESULTS: The mean values for total ADA and ADA2 activities in the serum and tumor of BBD were significantly higher than those of healthy controls (p <0.01).
  • Furthermore, the mean values for total ADA and ADA2 activities of patients with breast cancer were significantly higher than those of the benign group (p <0.005) and healthy subjects (p <0.0001).
  • CONCLUSIONS: Based on the present results, it is concluded that the assessment of total ADA and ADA2 activities may be used as a reliable test for differential diagnosis of benign and malignant breast disease.
  • [MeSH-major] Adenosine Deaminase / metabolism. Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 IMSS. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20430249.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


38. Wu ZS, Wu Q, Ding XD, Wang HQ, Shen YX, Fang SY: [Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance]. Zhonghua Bing Li Xue Za Zhi; 2008 Feb;37(2):109-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance].
  • OBJECTIVE: To investigate the expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance.
  • METHODS: AGR2 expression was assessed in 160 cases of breast cancer and 20 cases of benign breast diseases by immunohistochemistry using tissue chip technology.
  • In addition the expression of ERa, PR and c-erbB-2 in breast cancer was also evaluated.
  • Follow-up information of 5-year duration was available in 127 patients with breast cancer.
  • RESULTS: The expression of AGR2 was significantly higher in breast cancers than that in benign diseases (68.3% vs. 25.0% , P < 0.01).
  • There was a negative correlation between AGR2 expression and the histological grade of breast cancer (P <0.05) , whereas positive correlations was found between the expression of AGR2 and ERalpha (P <0.05), and between the expression of AGR2 and PR (P <0.01).
  • In the subgroup of ERalpha-positive breast cancer, Logistic regression model demonstrated AGR2 and TNM stage were important factors affecting lymph node metastasis (both P < 0.01).
  • Moreover, COX regression model confirmed the expression of AGR2 as an independent prognostic factor among patients with ERa-positive breast cancer (P <0.01).
  • CONCLUSIONS: The abnormal expression of AGR2 may play a role in the pathogenesis and progression of breast cancer.
  • Therefore, AGR2 may be a useful molecular marker for prognostication for patient with hormone-responsive breast cancer.
  • [MeSH-major] BRCA2 Protein / metabolism. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / genetics. Neoplasm Metastasis / diagnosis. Proteins / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Antineoplastic Agents, Hormonal / analysis. Biomarkers, Tumor / analysis. Estrogen Receptor alpha / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681322.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.3.4.1 / AGR2 protein, human
  •  go-up   go-down


39. Yao C, Wang SM, Xie D, Wu HX, Chen DY, Lin Y: [The relationship between expression of interleukin-8 and prognosis of breast cancer]. Zhonghua Wai Ke Za Zhi; 2006 Jul 1;44(13):900-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between expression of interleukin-8 and prognosis of breast cancer].
  • OBJECTIVE: To investigate the expression of interleukin-8 (IL-8) and its prognostic significance in breast cancer.
  • METHODS: Expression of IL-8 in 113 breast cancers, 19 breast benign tumors and 20 breast normal tissues was examined by tissue microarray using immunohistochemistry, and the association of IL-8 expression with patient's clinico-pathological characteristics and prognosis was further analyzed.
  • RESULTS: The positive rate of IL-8 expression in breast cancer was 27.4%, which was significantly higher than that in benign tumor and normal tissue of breast (P = 0.002).
  • CONCLUSIONS: IL-8 might be a poor prognostic factor for human breast cancer, and also might be a novel molecular marker to predicate the occurrence and progression of breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Interleukin-8 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Prognosis. Receptor, ErbB-2 / biosynthesis. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067482.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


40. Yavisheva TM, Shcherbakov SD, Golubeva IS, Savluchinskaya LA: Comparative analysis of the work of morphofunctional zones in normal epithelium, fibroadenoma, and cancer of the breast. Bull Exp Biol Med; 2005 Aug;140(2):231-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of the work of morphofunctional zones in normal epithelium, fibroadenoma, and cancer of the breast.
  • The number of cambial cells in morphofunctional zone of a malignant tumor is reduced at least 2-fold.
  • The percentage of cambial cells in a benign tumor decreases 1.5 times.
  • [MeSH-major] Breast Neoplasms / metabolism. Epithelium / metabolism. Fibroadenoma / metabolism
  • [MeSH-minor] Adult. Cell Differentiation. Cells, Cultured. Culture Techniques. Electromagnetic Fields. Female. Humans. Microscopy, Video. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16283009.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Crisi GM, Marconi SA, Makari-Judson G, Goulart RA: Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol; 2005 Nov;124(5):733-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit in adenoid cystic carcinoma of the breast.
  • Breast adenoid cystic carcinoma (BACC) is a biologically distinct tumor with morphologic mimickers, which might make accurate classification problematic.
  • All BACCs showed plasma membranous and cytoplasmic staining equal to or greater than that of adjacent benign epithelium.
  • Five BACCs (83%) expressed c-kit in more than 50% of tumor cells.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203286.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


42. Kowalski W, Mierzwa T, Grabiec M, Laskowski R, Walentowicz M: [Problems in diagnosing breast cancer in women younger than 25 years old]. Ginekol Pol; 2006 May;77(5):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Problems in diagnosing breast cancer in women younger than 25 years old].
  • OBJECTIVES: There are several challenges in the diagnosis of breast cancer in young women.
  • Special consideration must be given to the woman's fertility and body image issues, but the difficulty in distinguishing benign from malignant lesions in this group of patients still exists.
  • The aim of our study was to show five cases of breast cancer in young women.
  • MATERIALS AND METHODS: Based on 5 cases of breast cancer in women younger than 25, several methods used in diagnosis in this group of patients were discussed.
  • RESULTS: Diagnosing and treatment of young patients with breast cancer should be performed in specialized oncological centers experienced in dealing with breast cancer in very young women.
  • Because of the possibility of breast cancer in women under 25 years old, each case of breast tumor should be precisely diagnosed, especially by ultrasonography and biopsy (BAC) 2.
  • Each case suspected of breast cancer in young women should be diagnosed in highly equipped and specialized medical center.
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Mammography / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16958227.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


43. Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H: Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer; 2007 Jan 15;120(2):224-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progestins increase the risk of breast cancer in the hormone therapy of menopause, and progesterone receptor-induced fatty acid synthase (FAS) is a potential therapeutical target of breast cancer.
  • In a first attempt to specify in which lesions at risk of breast cancer progestins might be acting, we have compared the progesterone receptor (PR) and FAS expression in preinvasive breast lesions and in adjacent "normal" mammary glands.
  • We used archive paraffin-embedded tissues from 116 patients, with 164 lesions of increasing histological risk from nonproliferative "benign" breast disease (BBD) to in situ breast carcinomas.
  • The increased FAS expression, in lesions parallel to their increased breast cancer risk, suggests further studies to develop new markers of high-risk lesions and to prevent breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Cell Transformation, Neoplastic / metabolism. Fatty Acid Synthases / analysis. Receptors, Progesterone / analysis
  • [MeSH-minor] Adult. Aged. Early Diagnosis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044016.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


44. Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG: Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest; 2007 Feb;25(1):19-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
  • Epidemiologic and preclinical studies suggest that cyclooxygenase-2 (Cox-2) may promote tumor growth and spread by affecting angiogenesis and apoptosis in breast cancer.
  • Our TMA consisted of 669 Stage I-III primary breast cancers.
  • The total tumor and subcellular expression of Cox-2 were then correlated with clinicopathologic factors and with survival.
  • Cox-2 expression appeared higher in malignant than in benign tissue and was predominantly membrane/cytoplasmic (i.e. non-nuclear).
  • Multivariate analysis showed that Cox-2 remained a significant prognostic factor for survival independent of tumor size, nodal status, ER, Her2/neu, and grade.
  • In summary, Cox-2 is overexpressed in breast neoplasms, is associated with other markers of poor prognosis, and is significantly associated with worse survival independent of known prognostic factors.
  • Furthermore, AQUA and X-tile analysis suggest an optimal cutpoint that may be helpful in future investigations of Cox-2 and specifically, in studies looking at its expression as a predictive biomarker in clinical trials of Cox-2 inhibitors in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cyclooxygenase 2 / biosynthesis. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364553.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


45. Hes O, Sůvová B, Hlavácková M, Giebel P, Kinkor Z: [Harmatoma of the breast--case report]. Ceska Gynekol; 2006 Jul;71(4):351-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Harmatoma of the breast--case report].
  • [Transliterated title] Hamartom prsu--kazuistika.
  • OBJECTIVE: To describe rare hamartoma of the breast in a 31-year-old female.
  • SUBJECT AND METHOD: A 31-year-old female was examined for breast asymmetry.
  • A huge tumor was revealed in right mammary gland using ultrasonography.
  • Encapsulated tumor 10x10x10 cm was removed.
  • Subsequent histological examination revealed breast hamartoma.
  • CONCLUSION: Hamartoma of the breast is a rare benign tumor.
  • Diagnostics is very complicated and it is almost impossible to establish correct diagnosis preoperatively.

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956054.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


46. Malhaire C, El Khoury C, Thibault F, Athanasiou A, Petrow P, Ollivier L, Tardivon A: Vacuum-assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol; 2010 Jul;20(7):1554-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical accuracy of magnetic resonance imaging-guided breast vacuum-assisted biopsy (MR-VAB).
  • RESULTS: Twenty-three patients (median age 51 years) were at high risk (BRCA1 = 11, BRCA2 = 7, familial risk = 5), 23 had a suspected local recurrence of breast cancer.
  • According to histopathology results, 29 lesions were benign, 10 were high-risk (papillary = 2, radial scar = 1, atypical epithelial hyperplasia = 7) and 33 malignant (ductal carcinoma in situ = 8, invasive cancers = 25).
  • CONCLUSION: MRI-guided VAB represents an accurate tool for the histological diagnosis of lesions visible only at MRI.
  • [MeSH-major] Biopsy. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bleomycin. Breast / surgery. Dactinomycin. Female. Humans. Middle Aged. Neoplasm Staging. Radiography. Retrospective Studies. Tumor Burden. Vacuum. Vinblastine

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2004 Feb;198(2):240-1 [14759781.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):347-51 [12540431.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1725-31 [15248080.001]
  • [Cites] AJR Am J Roentgenol. 2008 Dec;191(6):1798-804 [19020252.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):721-7 [11222213.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):468-74 [17646475.001]
  • [Cites] Acta Radiol. 2006 Nov;47(9):907-13 [17077039.001]
  • [Cites] AJR Am J Roentgenol. 2009 Apr;192(4):1128-34 [19304724.001]
  • [Cites] AJR Am J Roentgenol. 2003 Nov;181(5):1283-93 [14573421.001]
  • [Cites] Radiology. 2006 Jan;238(1):54-61 [16304093.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):171-8 [12076929.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1782-7 [15908530.001]
  • [Cites] AJR Am J Roentgenol. 2009 Feb;192(2):341-51 [19155393.001]
  • [Cites] Eur J Radiol. 2009 Nov;72(2):289-94 [18723305.001]
  • [Cites] Am J Hum Genet. 1991 Feb;48(2):232-42 [1990835.001]
  • [Cites] Lancet. 2005 May 21-27;365(9473):1769-78 [15910949.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3248-58 [18474876.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):386-91 [18202414.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):852-9 [17885056.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):352-3 [18202408.001]
  • [Cites] Radiology. 2007 Aug;244(2):356-78 [17641361.001]
  • [Cites] Radiology. 2007 Sep;244(3):672-91 [17709824.001]
  • [Cites] Eur Radiol. 2002 Jun;12(6):1463-70 [12042955.001]
  • [Cites] Radiology. 1999 Aug;212(2):543-9 [10429716.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):982-90 [16456807.001]
  • [Cites] Eur Radiol. 1999;9(8):1656-65 [10525886.001]
  • [Cites] Radiology. 2007 Aug;244(2):381-8 [17641362.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1733-6 [16714667.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1323-9 [10541112.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):183-93 [15972421.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Eur Radiol. 2008 Jan;18(1):168-76 [17609959.001]
  • (PMID = 20119729.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5V9KLZ54CY / Vinblastine; VAB protocol
  •  go-up   go-down


47. Salemi M, Calogero AE, Vicari E, Migliore E, Zaccarello G, Cosentino A, Amore M, Tricoli D, Castiglione R, Bosco P, Rappazzo G: A high percentage of skin melanoma cells expresses SPANX proteins. Am J Dermatopathol; 2009 Apr;31(2):182-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of SPANX (sperm protein associated with the nucleus in the X chromosome) gene family has been reported in many tumors, such as melanoma, myeloma, glioblastoma, breast carcinoma, ovarian cancer, testicular germ cell tumors, and hematological malignancies.
  • The expression of SPANX proteins was evaluated by immunohistochemistry in normal skin (n = 12), melanomas (n = 21), and benign nevi (n = 10), using a polyclonal antibody raised in our laboratory.
  • Benign nevi had an intermediate number of cells expressing SPANX proteins (25% +/- 8.5%), which resulted significantly higher than normal skin cells and significantly lower than skin melanoma cells.
  • In melanoma cells, the labeling was mostly nuclear, sometimes incomplete or limited to the perinuclear wall, even if cytoplasmic staining was also seen in SPANX-positive tumor cells.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies. Antibody Specificity. Biopsy. Epitopes / immunology. Epitopes / metabolism. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Multigene Family / physiology. Neoplasms / metabolism. Neoplasms / pathology. Nevus / metabolism. Nevus / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318807.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Epitopes; 0 / Nuclear Proteins; 0 / SPANXA1 protein, human
  •  go-up   go-down


48. Kim JE, Kim HJ, Choi JM, Lee KH, Kim TY, Cho BK, Jung JY, Chung KY, Cho D, Park HJ: The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol; 2010 Nov;163(5):959-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent evidence suggests cathelicidin LL-37 to be a growth factor for various human cancers such as lung cancer, ovarian cancer and breast cancer.
  • Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed.
  • [MeSH-major] Antimicrobial Cationic Peptides / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor / metabolism. Cell Movement / physiology. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Precancerous Conditions / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20977442.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 143108-26-3 / CAP18 lipopolysaccharide-binding protein
  •  go-up   go-down


49. Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG: BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer. Breast Cancer Res Treat; 2008 Oct;111(3):505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.
  • Several studies in various populations have suggested that non-synonymous BARD1 variants are associated with increased breast cancer risk.
  • Using DHPLC analysis we screened the coding region of BARD1 for variants in 210 probands of breast cancer families including 129 families with no mutations in BRCA1 or BRCA2.
  • These families were ascertained in Australia through the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
  • The frequency of five of these variants were evaluated in 258 non-cancer controls and 401 women with sporadic breast cancer.
  • Two variants (Thr598Ile and Ile692Thr) were not detected in any of the 659 sporadic breast cancer cases and controls and were assessed for segregation with breast cancer in the families of the probands.
  • However, neither variant was identified in any other breast cancer case in either family suggesting that these variants are non-pathogenic polymorphisms.
  • We have found no evidence to support involvement of BARD1 in familial breast cancer risk in the Australian population.
  • In addition, three variants previously reported to be pathogenic in other populations are likely to represent benign polymorphisms and therefore we conclude that BARD1 is unlikely to represent a high-penetrance breast cancer susceptibility gene.
  • [MeSH-major] Breast Neoplasms / genetics. Polymorphism, Genetic. Tumor Suppressor Proteins / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Australia. Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Pedigree. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972171.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BARD1 protein, human; 0 / Tumor Suppressor Proteins; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


50. Atallah D, Checrallah A, Rouzier R, Ghossain MA, Chahine G: Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):762-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy.
  • CASE: A 44-year-old premenopausal woman with breast cancer treated with adjuvant tamoxifen presented with abdominal distension.
  • We speculate that tamoxifen treatment may play a role in the development of this benign tumor.
  • [MeSH-major] Lymphangiomyoma / diagnosis. Ovarian Neoplasms. Retroperitoneal Neoplasms / diagnosis. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018494.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


51. Li BJ, Wang JY, Wang HY, Huang XP, Zhang LJ, Long H, Yang MT, Rong TH: [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient]. Zhonghua Zhong Liu Za Zhi; 2006 Oct;28(10):766-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
  • OBJECTIVE: To investigate the expression of the human mammoglobin (hMAM) mRNA in bone marrow and its clinical significance in the breast cancer patient.
  • METHODS: Expression of hMAM mRNA was detected using nested reverse transcription polymerase chain reaction (RT-PCR) in the bone marrow aspiration sample from 75 breast cancer patients, 15 patients with benign breast lesions and 8 healthy volunteers as control.
  • The hMAM mRNA was found to be positively expressed by RT-PCR in 21 of 75 breast cancer patients with a positive rate of 28.0%.
  • However, hMAM mRNA expression was not detected in the bone marrow aspiration samples from patients with benign breast lesions and healthy volunteers.
  • The hMAM mRNA expression was positively correlated with axillary nodal involvement and progesterone receptor (PR) status (P < 0.05) as well as Ki67 expression in breast cancer tissue (chi2 = 4.936, P = 0.026), but not with age, tumor size, clinical stage, or estrogen receptor (ER) status (P > 0.05).
  • CONCLUSION: RT-PCR is quite sensitive and has a high specificity in detecting the presence of hMAM mRNA in the bone marrow from breast cancer patients.
  • Thereupon, hMAM mRNA may be useful as a molecular biomarker in detecting disseminated tumor cells (DTC) in the bone marrow of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / genetics. Breast Neoplasms, Male / genetics. Neoplasm Proteins / genetics. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Fibroadenoma / genetics. Fibroadenoma / pathology. Humans. Ki-67 Antigen / genetics. Lymphatic Metastasis. Male. Mammaglobin A. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Progesterone / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366790.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


52. Sanati S, Leonard M, Khamapirad T, Eltorky MA: Nodular mucinosis of the breast: a case report with pathologic, ultrasonographic, and clinical findings and review of the literature. Arch Pathol Lab Med; 2005 Mar;129(3):e58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular mucinosis of the breast: a case report with pathologic, ultrasonographic, and clinical findings and review of the literature.
  • Nodular mucinosis is an extremely rare breast lesion.
  • This benign mass usually presents clinically as a poorly circumscribed, subareolar, myxoid mass in young female patients.
  • We report a case of this rare breast lesion and discuss its clinical, radiologic, and histopathologic features.
  • A 21-year-old white woman presented with a mass in the left breast of 6 months' duration.
  • She had never been pregnant or had any history of breast feeding, surgery, trauma, or use of exogenous hormones or a family history of breast cancer.
  • Clinical breast examination demonstrated a 1 cm "rubbery" mass directly under and continuous with the left nipple.
  • These findings suggested a benign breast lesion, including a fibroadenoma or nipple adenoma.
  • Microscopic examination showed a well-circumscribed tumor with a nodular appearance, which consisted of an accumulation of pink myxoid tissue and contained spindle cells with bland-appearing nuclei, no mitosis, and mild cellularity.
  • [MeSH-major] Breast / pathology. Mucinoses / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737051.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


53. Cao D, Tsangaris TN, Kouprina N, Wu LS, Balch CM, Vang R, Argani P: The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling. Ann Surg Oncol; 2008 May;15(5):1330-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling.
  • METHODS: 168 SSMs with a small, additional superficial margin (ASM) specimen taken directly over the tumor to the dermis intraoperatively were studied.
  • RESULTS: 64 SSMs (38%) had a positive superficial specimen margin but only 13 (20%) of these had residual breast carcinoma in ASMs.
  • Only 1 of 104 SSMs with a negative superficial specimen margin had residual breast carcinoma in its ASM (P < 0.05).
  • ASM sampling rendered the final true margin directly over the tumor negative in 54 of 58 (93%) SSMs with a focally positive superficial specimen margin, but did not negate the nonfocally positive superficial specimen margin in six other cases.
  • In SSMs with a positive superficial specimen margin, multivariate analysis revealed that the presence of extensive ductal carcinoma in situ (DCIS) in the SSM and a thicker ASM specimen were the only independent factors predictive of residual breast carcinoma in ASM.
  • Eighty-nine (53%) ASMs contained benign breast tissue.
  • CONCLUSIONS: Superficial specimen margins in SSMs are often microscopically positive and approximately half of ASMs contain benign breast tissue, likely reflecting the difficulty in completely removing breast tissue near the skin flaps in SSMs.
  • ASM sampling effectively decreases positive superficial specimen margins directly over the tumor in SSMs, but fails to account for positive superficial specimen margins in other quadrants in patients with multicentric disease, especially extensive DCIS.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1999 Aug;104(2):421-5 [10654685.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):438-43 [17826052.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1619-25 [11920520.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):814-9 [12035037.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):706-11 [12560691.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):712-20; discussion 721-2 [12560692.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):102-7 [12620902.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):108-12 [12620903.001]
  • [Cites] Am J Surg. 2004 Jul;188(1):78-84 [15219490.001]
  • [Cites] Surg Gynecol Obstet. 1966 Mar;122(3):529-40 [5908662.001]
  • [Cites] Ann Surg. 1983 Mar;197(3):284-7 [6830336.001]
  • [Cites] Plast Reconstr Surg. 1991 Jun;87(6):1048-53 [1852020.001]
  • [Cites] Plast Reconstr Surg. 1991 Sep;88(3):389-92; discussion 393-4 [1871214.001]
  • [Cites] Am J Clin Pathol. 1992 Jul;98(1):125-37 [1615916.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1746-51 [8082077.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):411-6 [8790856.001]
  • [Cites] Ann Surg. 1997 May;225(5):570-5; discussion 575-8 [9193184.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1740-5 [9351542.001]
  • [Cites] Plast Reconstr Surg. 1998 Jul;102(1):49-62 [9655407.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):456-63 [9718177.001]
  • [Cites] Ann Surg Oncol. 1998 Oct-Nov;5(7):620-6 [9831111.001]
  • [Cites] Breast. 2004 Dec;13(6):488-93 [15563856.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):606-8 [16164932.001]
  • [Cites] Breast J. 2005 Sep-Oct;11(5):374-5 [16174169.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1625-32 [16327435.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1037-44 [16244800.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Int J Clin Oncol. 2006 Feb;11(1):51-4 [16508729.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):1074-8; discussion 1078-80 [17481544.001]
  • [Cites] Cancer J. 2000 Sep-Oct;6(5):331-5 [11079173.001]
  • (PMID = 18246402.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; None / None / / P50 CA088843-06A19005; United States / NCI NIH HHS / CA / P50 CA088843-06A19005
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS243747; NLM/ PMC2958107
  •  go-up   go-down


54. Yang DM, Kim HC, Lim JW, Jin W, Ryu CW, Kim GY, Cho H: Sonographic findings of groin masses. J Ultrasound Med; 2007 May;26(5):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common benign tumor of the inguinal region was a lipoma.
  • Other benign tumors of the groin included leiomyomas, dermoid cysts, epidermoid cysts, and lymphangiomas.
  • Secondary malignant tumors of the inguinal regions were metastatic lymphomas and metastatic carcinomas of the lung, breast, ovary, and gastrointestinal tract.
  • CONCLUSIONS: Although there was substantial overlap of sonographic findings in the various inguinal masses, clinical history and certain sonographic details can assist in making the correct diagnosis.
  • [MeSH-minor] Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460003.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Riedl CC, Pfarl G, Memarsadeghi M, Wagner T, Fitzal F, Rudas M, Helbich TH: Lesion miss rates and false-negative rates for 1115 consecutive cases of stereotactically guided needle-localized open breast biopsy with long-term follow-up. Radiology; 2005 Dec;237(3):847-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lesion miss rates and false-negative rates for 1115 consecutive cases of stereotactically guided needle-localized open breast biopsy with long-term follow-up.
  • PURPOSE: To retrospectively determine the lesion miss rate and false-negative rate of needle-localized open breast biopsy (NLOBB) with stereotactic guidance in a large study population.
  • The mammographic outcomes in all patients with benign results at NLOBB were tracked for at least 2 years.
  • Cases without such mammographic follow-up were cross-referenced with a tumor registry after at least 54 months.
  • Mammographic follow-up data were available for 535 (83%) of 643 NLOBBs with benign results.
  • Mammographic follow-up revealed 11 lesions that were missed with NLOBB, of which five were malignant and six benign.
  • Among the 643 cases, in 108 of them without mammographic follow-up (17%), cross-referencing with a tumor registry did not reveal missed cases of breast carcinoma.
  • CONCLUSION: On the basis of the results of long-term follow-up, the authors noted a lesion miss rate of 1.1% and a false-negative rate of 1.0%, which indicate that NLOBB with stereotactic guidance is an accurate method for diagnosing breast lesions.
  • [MeSH-major] Biopsy, Needle / methods. Breast Diseases / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Diagnostic Errors. False Negative Reactions. Female. Humans. Mammography. Middle Aged. Registries. Retrospective Studies. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005
  • (PMID = 16237133.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ: Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma. Am J Surg Pathol; 2007 Jan;31(1):129-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.
  • Retraction artifact resulting in clear spaces around tumor cell nests is frequently seen in histologic material and may present difficulty in their differentiation from lymphovascular invasion.
  • We noticed that retraction artifact seemed to be more common around groups of breast cancer cells compared with benign acini, and when extensively present, metastasis to axillary lymph nodes was often seen.
  • Thus, we performed a study of 304 cases of stage pT1 and pT2 breast carcinomas to test our hypothesis that extensive retraction artifact in tumors correlates with lymphatic spread and outcome.
  • Tumors were evaluated to determine the presence and extent of retraction artifact around tumor cell nests and the presence of lymphatic invasion.
  • The extent of retraction artifact in tumors was correlated with clinicopathologic tumor features and patient outcome.
  • The extent of retraction artifact showed a significant correlation with tumor size, histologic type, histologic grade, presence of lymphovascular invasion, and nodal metastasis.
  • We propose that the apparent retraction of the stroma from cells of invasive breast carcinoma on routine histologic sections is not a phenomenon merely due to inadequate fixation as currently believed.
  • Rather, it likely signifies important biologic changes that alter tumor-stromal interactions and contribute to lymphatic spread and tumor progression.
  • [MeSH-major] Artifacts. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Histocytological Preparation Techniques. Lymph Nodes / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Early Diagnosis. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. ROC Curve. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197929.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


57. Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Sadanaga N, Yamamoto H, Honda H: Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging; 2008 Nov;28(5):1157-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
  • PURPOSE: To evaluate the diagnostic accuracy of a combination of dynamic contrast-enhanced MR imaging (DCE-MRI) and diffusion-weighted MR imaging (DWI) in characterization of enhanced mass on breast MR imaging and to find the strongest discriminators between carcinoma and benignancy.
  • MATERIALS AND METHODS: We analyzed consecutive breast MR images in 270 patients; however, 13 lesions in 93 patients were excluded based on our criteria.
  • We analyzed tumor size, shape, margin, internal mass enhancement, kinetic curve pattern, and apparent diffusion coefficient (ADC) values.
  • We added the corresponding categories to these prediction probabilities for malignancy and calculated diagnostic accuracy when we consider category 4b, 4c, and 5 lesions as malignant and category 4a, 3, and 2 lesions as benign.
  • CONCLUSION: The combination of DWI and DCE-MRI could produce high diagnostic accuracy in the characterization of enhanced mass on breast MR imaging.
  • [MeSH-major] Algorithms. Breast / pathology. Breast Neoplasms / diagnosis. Gadolinium DTPA. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18972357.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


58. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP: Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest; 2008 Mar;26(2):159-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast.
  • OBJECTIVE: The objective of this study was to determine if protein-by-products secondary to cancer related oncogenes appear in the saliva of breast cancer patients.
  • One pooled specimen was from healthy women, another pooled specimen from women diagnosed with a benign breast tumor and the other one pooled specimen was from women diagnosed with ductal carcinoma in situ (DCIS).
  • Differential expression of proteins was measured by isotopically tagging proteins in the tumor groups and comparing them to the healthy control group.
  • Forty-nine proteins were differentially expressed between the healthy control pool and the benign and cancer patient groups.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Fibroadenoma / metabolism. Neoplasm Proteins / metabolism. Saliva / metabolism. Salivary Proteins and Peptides / metabolism
  • [MeSH-minor] Female. Humans. Middle Aged. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259946.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Salivary Proteins and Peptides
  •  go-up   go-down


59. Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z: Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res; 2009 Jun;7(6):832-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer.
  • But its function in breast cancer was not yet clarified completely.
  • We detected RKIP expression in clinical samples of primary breast cancer, breast cancer metastases, and in different breast cancer cells.
  • Compared with the normal breast epithelia, benign breast epithelia, or in situ ductal carcinoma, the expression level of RKIP is decreased in invasive carcinoma and significantly reduced or lost in the metastasis lymph node matched to the invasive carcinoma.
  • To explore the potential role of RKIP in breast cancer metastasis, we studied the effect of RKIP on the malignant phenotypes of the breast cancer cells with ectopically overexpression or knockdown of RKIP.
  • Consistent with these results, in the orthotopic murine models, we observed that overexpression of RKIP in breast cancer cells impaired invasiveness and metastasis, whereas down-regulation of RKIP expression promoted invasiveness and metastasis.
  • These results indicate that RKIP is a metastasis suppressor gene of human breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / biosynthesis
  • [MeSH-minor] Analysis of Variance. Animals. Cell Adhesion / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Neoplasm Metastasis. Neovascularization, Pathologic / metabolism. Statistics, Nonparametric. Tissue Distribution


60. Ferbeyre-Binelfa L, Ramírez-Bollas J, Bautista-Piña V, Espejo-Fonseca R, Ruvalcaba-Limón E, Serratos-Garduño E: [Fibromatosis of the breast. Report of two cases and review of the literature]. Cir Cir; 2009 Jul-Aug;77(4):313-8; 291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibromatosis of the breast. Report of two cases and review of the literature].
  • BACKGROUND: Fibromatosis is a term used to describe a group of lesions characterized by well-differentiated fibroblast proliferation with an usually benign biological behavior but with an infiltrative pattern of growth, frequently recurrent and locally invasive.
  • The presence of this entity in breast tissue is an uncommon clinical situation, comprising approximately 0.2% of breast tumors and very often misdiagnosed as malignant disease or phyllodes tumor.
  • In this rare condition, immunohistochemistry is an important diagnostic tool in anatomopathological differential diagnosis with other spindle cell tumors of the breast.
  • CLINICAL CASES: We present two cases of breast fibromatosis confirmed immunohistochemically and also by biopsy.
  • One case had the clinical and imaging appearance of breast carcinoma with the classic irregular mass presentation and the other case was misdiagnosed as phyllodes tumor because of the size and density of the tumor and the cytology.
  • CONCLUSIONS: Approximately 83 cases of breast fibromatosis have been reported during the last 30 years, including one male patient.
  • We reviewed clinicopathological features of two cases of fibromatosis of the breast treated at our institute.
  • [MeSH-major] Breast Neoplasms / diagnosis. Fibroma / diagnosis
  • [MeSH-minor] Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919794.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 44
  •  go-up   go-down


61. Chang RF, Huang SF, Moon WK, Lee YH, Chen DR: Computer algorithm for analysing breast tumor angiogenesis using 3-D power Doppler ultrasound. Ultrasound Med Biol; 2006 Oct;32(10):1499-508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer algorithm for analysing breast tumor angiogenesis using 3-D power Doppler ultrasound.
  • Angiogenesis provides blood supply for tumor expansion and also increases the opportunity for tumor cells to enter the blood or lymph circulation.
  • Several proangiogenic factors as well as the contribution of the microenvironment to tumor-induced angiogenesis have been identified.
  • Tumor vessels are structurally and functionally abnormal because of an imbalance of these angiogenic regulators.
  • In contrast to normal vessels, tumor vasculature is highly disorganized, tortuous and dilated, with uneven diameter and excessive branching.
  • In investigations into 221 solid breast tumors, including 110 benign and 111 malignant cases, the p values using the Student's t-test for all features were less than 0.05, indicating that the proposed features were deemed statistically significant.
  • The preliminary results show that the proposed method is feasible and has a good agreement with the diagnosis of the pathologists.
  • [MeSH-major] Algorithms. Breast Neoplasms / ultrasonography. Neovascularization, Pathologic / ultrasonography. Ultrasonography, Doppler, Color / methods
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / blood supply. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / ultrasonography. Female. Humans. Image Processing, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Middle Aged. Neural Networks (Computer). ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045870.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Guo Z, Wang Z, Li J, Li XD: [Reconstruction with a new type of combined reconstruction following excision of periacetabular tumors]. Zhonghua Wai Ke Za Zhi; 2008 Jun 15;46(12):895-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the reconstructive effect of a new pattern of combined reconstruction after periacetabular tumor resections.
  • METHODS: Between March 2001 and March 2007, tumor resections and new pattern of combined reconstructions which consisted of screw-rod system, acetabular reinforcement shell, antibiotic cement and total hip arthroplasty techniques were performed in 23 patients with periacetabular tumors.
  • Three metastatic bone tumors were also included in this study, and the original sites were thyroid, breast, and ovary.
  • Three primary benign bone tumors belonged to stage III.
  • CONCLUSIONS: This new combined reconstruction is an effective way to rebuild pelvic ring and maintain hip function with low complication rate after periacetabular tumor resections.
  • [MeSH-minor] Adolescent. Adult. Aged. Arthroplasty, Replacement, Hip. Bone Screws. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035146.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Nalini R, Wilma Delphine Silvia CR, Uthappa S: Utility of blood DNA levels in diagnosis of breast cancer. J Cancer Res Ther; 2008 Apr-Jun;4(2):57-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of blood DNA levels in diagnosis of breast cancer.
  • BACKGROUND: Prognostic factors, including both histopathological and biochemical variables, influence the choice of modality and the course of therapy in breast cancer.
  • AIM: To find out if any correlation exists between blood DNA level and tumor stage, size and grade.
  • MATERIALS AND METHODS: This case-control study was carried out on 52 female patients in the age-group of 18-70 years.
  • The cases comprised 25 patients with histopathologically confirmed malignant breast cancer, while 27 patients with benign breast tumors served as the control group.
  • Pearson's test was performed to find out the correlation between blood DNA levels and the TNM stage, tumor size and grade.
  • RESULTS: It was observed that blood DNA levels showed statistically significant correlation with the TNM stage, tumor size and grade.
  • CONCLUSION: The blood DNA level can be utilized as a noninvasive marker to assess tumor aggressiveness.
  • Thus, it can be useful as a prognostic marker and as a marker of tumor burden.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. DNA, Neoplasm / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms / diagnosis. Neoplasms / surgery. Tumor Burden

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688119.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


64. Li C, Grobmyer SR, Chen L, Zhang Q, Fajardo LL, Jiang H: Multispectral diffuse optical tomography with absorption and scattering spectral constraints. Appl Opt; 2007 Dec 1;46(34):8229-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initial clinical results indicate that the volume fraction of scattering particles in a malignant tumor is higher than that in a benign tumor.
  • [MeSH-minor] Body Water. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Computer Simulation. Female. Hemoglobins / analysis. Humans. Linear Models. Middle Aged. Oxyhemoglobins / analysis. Particle Size. Phantoms, Imaging. Water / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059661.001).
  • [ISSN] 0003-6935
  • [Journal-full-title] Applied optics
  • [ISO-abbreviation] Appl Opt
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Oxyhemoglobins; 059QF0KO0R / Water; 9008-02-0 / deoxyhemoglobin
  •  go-up   go-down


65. Kraemer B, Hoffmann J, Roehm C, Gall C, Wallwiener D, Krainick-Strobel U: Cystosarcoma phyllodes of the breast: a rare diagnosis: case studies and review of literature. Arch Gynecol Obstet; 2007 Dec;276(6):649-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystosarcoma phyllodes of the breast: a rare diagnosis: case studies and review of literature.
  • Cystosarcoma phyllodes (CP), otherwise known as phyllodes tumour (PT) of the breast, is a very rare but locally aggressive fibroepithelial tumour in its malignant form, and accounts for 0.3-1% of all breast neoplasias.
  • Using 4 cases reports with different histological classifications as examples (benign-borderline-malignant), we describe the (differential) diagnosis and treatment options of this tumour entity and give an additional review of the available literature.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Phyllodes Tumor / pathology. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Mastectomy, Extended Radical. Mastectomy, Segmental. Middle Aged

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549503.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


66. Zúbor P, Kajo K, Dussan CA, Szunyogh N, Danko J: Rapidly growing nodular pseudoangiomatous stromal hyperplasia of the breast in an 18-year-old girl. APMIS; 2006 May;114(5):389-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing nodular pseudoangiomatous stromal hyperplasia of the breast in an 18-year-old girl.
  • Pseudoangiomatous stromal hyperplasia (PASH) of the breast is a rare benign proliferation of mesenchymal stromal cells with irregular slit-like formations resembling angiomatous structures.
  • In the majority of cases this lesion is a focal microscopic finding in breast biopsies performed for benign or malignant diseases.
  • The exact etiology and pathogenesis of this tumor-like lesion is still unknown, but a proliferative response of myofibroblasts to hormonal stimuli has been postulated.
  • A large 12 x 9 x 3.5 cm rapidly growing nodular form of PASH of the breast in an 18-year-old woman is here described with clinical and histological findings.
  • To the authors' knowledge this is only the fourth case of nodular PASH of the breast reported in the English literature.
  • [MeSH-major] Breast / cytology. Breast / pathology. Breast Neoplasms / diagnosis. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Adolescent. Anovulation. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology. Progesterone / blood. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Pseudoangiomatous stromal hyperplasia.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16725017.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


67. Thorat MA, Morimiya A, Mehrotra S, Konger R, Badve SS: Prostanoid receptor EP1 expression in breast cancer. Mod Pathol; 2008 Jan;21(1):15-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostanoid receptor EP1 expression in breast cancer.
  • In this study, we analysed the expression of EP1 in normal and malignant breast tissues.
  • Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses.
  • Expression was also analysed by immunohistochemistry in normal breast tissues and in 89 cases of breast cancer.
  • EP1 expression was demonstrated in human breast cancer by immunohistochemistry.
  • Expression of EP1 is frequently seen in human breast cancers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Receptors, Prostaglandin E / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Nucleus / chemistry. Cyclooxygenase 2 / analysis. Cytoplasm / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Receptors, Prostaglandin E, EP1 Subtype. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906615.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37403; United States / NIAMS NIH HHS / AR / K08 AR
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PTGER1 protein, human; 0 / Ptger1 protein, mouse; 0 / Ptger1 protein, rat; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP1 Subtype; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


68. Mahmoud A, Hill DH, O'Sullivan MJ, Bennett MW: Cylindroma of the breast: a case report and review of the literature. Diagn Pathol; 2009;4:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindroma of the breast: a case report and review of the literature.
  • Cylindroma of the breast is a very rare lesion which is morphological and immunophenotypically identical to benign dermal cylindroma.
  • We report a breast cylindroma in a previously healthy 62 year old female detected through a national breast screening program.
  • The patient had no significant family or past medical history, and specifically no history of breast or skin diseases.
  • The tumor consisted of well circumscribed islands of epithelial cells surrounded by a dense membrane material, and focally containing hyaline globules.
  • At low power the islands of tumour cells formed a "jig-saw" pattern, which is typical of cylindroma, but was present within normal breast parenchyma and no had direct connection with the overlying skin.
  • We discuss the nine previously reported cases and the distinction of breast cylindroma from adenoid cystic carcinoma, the main differential diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725978.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224926
  •  go-up   go-down


69. Di Carlo A, Terracciano D, Mariano A, Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol; 2005 May;26(5):1363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, several MMPs were implicated in creating an environment that supports the initiation and maintenance of tumor growth.
  • Of these patients, 22 had malignant pleural effusion, consisting of 11 breast carcinomas and 11 lung carcinomas (7 squamous cell carcinomas and 4 adenocarcinomas), and 8 patients had benign effusions.
  • The MMP-9/MMP-2 ratio was enhanced in cancer patients compared with benign diseases and healthy individuals.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Pleural Effusion / enzymology. Pleural Effusion / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809729.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


70. de León DC, Montiel DP, Nemcova J, Mykyskova I, Turcios E, Villavicencio V, Cetina L, Coronel A, Hes O: Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients. BMC Cancer; 2009;9:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients.
  • BACKGROUND: Breast cancer is one of the main health problems in developed countries, occupying first place in mortality in women.
  • It is well-known that there are risk factors associated with breast cancer development.
  • Nonetheless, in 50-80% of cases known risk factors have not been identified, this has generated the attempt to identify new factors related with this neoplasia as viral infections.
  • The aim of this work is investigate the prevalence of HPV DNA in patients with breast lesions at the Instituto Nacional de Cancerologia de Mexico.
  • METHODS: Fifty-one cases of breast cancer were selected from the files of the institute and compared by age and tumor size with 43 cases of non malignant breast lesions (fibroadenoma, fibrocystic disease and phyllodes tumor).
  • RESULTS: All patients were mexican, mean age was 53.3, median age of menarche was 13 and median tumor size 9 cms.
  • In the group of benign conditions all were negative to HPV-DNA.
  • CONCLUSION: Presence of HPV in breast cancer in our group of cases is high in comparison to other authors; larger numbers of cases need to be analyzed in order to establish the exact role of this virus in the pathogenesis of breast cancer.
  • [MeSH-major] Breast Neoplasms / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / isolation & purification. Female. Humans. Mexico. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2007 Apr;16(2):172-7 [17088061.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):369-77 [10606184.001]
  • [Cites] Acta Oncol. 1999;38(7):931-8 [10606422.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):5057-61 [10697510.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):33-6 [11029768.001]
  • [Cites] J Hum Virol. 2001 Nov-Dec;4(6):329-34 [12082399.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6 [12488476.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Pathol Res Pract. 1992 Apr;188(3):384-6 [1320761.001]
  • [Cites] Breast Cancer Res Treat. 1992;21(2):95-100 [1320958.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(2):121-35 [10326789.001]
  • [Cites] J Clin Microbiol. 1999 Aug;37(8):2508-17 [10405393.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):946-8 [16222323.001]
  • [Cites] Clin Breast Cancer. 2005 Dec;6(5):391-401 [16381622.001]
  • [Cites] J Pathol. 2006 Aug;209(4):436-44 [16710841.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(1):55-8 [17624590.001]
  • (PMID = 19161629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2636825
  •  go-up   go-down


71. Lewis CM, Cler LR, Bu DW, Zöchbauer-Müller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM: Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res; 2005 Jan 1;11(1):166-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
  • INTRODUCTION: The tumor suppressor genes RASSF1A, APC, H-cadherin, RARbeta2, and cyclin D2 are methylated more frequently in breast cancer than in adjacent benign tissue.
  • However, it is unclear whether promoter methylation of tumor suppressor genes in benign breast tissue is associated with an increased risk for breast cancer.
  • METHODS: Promoter hypermethylation was measured in benign and malignant breast samples obtained by fine needle aspiration biopsy from 27 breast cancer patients and 55 unaffected women whose risk of breast cancer had been defined using the Gail, Claus, and BRCAPRO models.
  • RESULTS: Cyclin D2 methylation occurred in 57% of tumor samples but not in corresponding benign breast samples and in only one sample from an unaffected patient (P < 0.0001).
  • RARbeta2 methylation occurred in 32% of benign breast samples from cancer patients but only 9% of similar samples from unaffected women (P = 0.002).
  • Promoter methylation of RASSF1A and APC occurred more frequently (70% and 56%, respectively) in unaffected women at high-risk for breast cancer as defined by the Gail model than in low/intermediate risk women (29% and 20%, P = 0.04 and P = 0.03).
  • Of the Gail model risk factors, only number of prior breast biopsies was highly correlated with APC and RASSF1A methylation (P = 0.0001 and 0.02, respectively).
  • CONCLUSIONS: Since cyclin D2 promoter methylation occurs almost exclusively in tumors, it may be possible to exploit it for the early detection of breast cancer.
  • Promoter methylation of APC, RARbeta2, and RASSF1A in benign breast epithelium is associated with epidemiologic markers of increased breast cancer risk.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. DNA Methylation. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Age Factors. Aged. Biopsy. Breast / pathology. Cadherins / biosynthesis. Cyclin D2. Cyclins / biosynthesis. Female. Humans. Middle Aged. Models, Theoretical. Polymerase Chain Reaction. Protein C / biosynthesis. Receptors, Retinoic Acid / biosynthesis. Risk. Tumor Suppressor Proteins / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671542.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA71618
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cadherins; 0 / Cyclin D2; 0 / Cyclins; 0 / H-cadherin; 0 / Protein C; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  •  go-up   go-down


72. Cui Y, Koop EA, van Diest PJ, Kandel RA, Rohan TE: Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer. Breast Cancer Res Treat; 2007 Jul;104(1):103-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer.
  • Certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients.
  • However, the application of these features to predicting risk of breast cancer development has received little attention.
  • We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.
  • The study was nested within a cohort of 4,888 women with a histopathologic diagnosis of benign breast disease (BBD) and involved 61 cases and 71 controls, amongst whom there were 53 matched case-control sets.
  • Conditional logistic regression models were fitted to assess various measurements of nuclear size and nuclear shape factors in relation to subsequent breast cancer risk.
  • In multivariate analysis, subsequent breast cancer risk was positively associated with a nuclear shape factor that takes the shortest nuclear axis and the longest nuclear axis into consideration simultaneously (highest quartile versus lowest 3 quartiles: odds ratio = 3.07, 95% confidence limits = 1.61, 5.84).
  • In contrast, there was no alteration in subsequent breast cancer risk in association with nuclear size features and other shape factors.
  • In conclusion, our study results suggest that the shape factor that takes both the shortest nuclear axis and the longest nuclear axis into consideration might be of value to predict subsequent development of breast cancer among women with BBD.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / epidemiology
  • [MeSH-minor] Adult. Canada / epidemiology. Case-Control Studies. Cohort Studies. Female. Humans. Middle Aged. Registries. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2002 Oct 15;59(2):109-18 [12373721.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):282-5 [11494225.001]
  • [Cites] Histopathology. 2004 Oct;45(4):352-9 [15469473.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):9-18 [7123847.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):603-9 [3722413.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):270-5 [2381167.001]
  • [Cites] Anal Cell Pathol. 1989 Feb;1(1):11-23 [2562217.001]
  • [Cites] Eur J Surg Oncol. 1991 Aug;17(4):350-3 [1874292.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1459-76 [1423087.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):374-82 [8908309.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Urology. 1999 Jan;53(1):44-9 [9886586.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(5):257-61 [10392302.001]
  • [Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72 [15824141.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):297-9 [16034016.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3542-8 [10589770.001]
  • [Cites] Pathol Res Pract. 1999;195(11):741-6 [10605693.001]
  • [Cites] Pol J Pathol. 1999;50(4):235-41 [10721263.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):494-9 [11102893.001]
  • [Cites] J Pathol. 2001 Jan;193(1):33-9 [11169513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59 [11303595.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • (PMID = 17061043.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2092407
  •  go-up   go-down


73. Rabban JT, Koerner FC, Lerwill MF: Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol; 2006 Jul;37(7):787-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
  • Most of the epithelial cells of UDH express cytokeratin 5/6, but the tumor cells of ductal carcinoma in situ do not.
  • None of the SP-DCIS tumor cells stained for cytokeratin 5/6; however, many cases did show staining of occasional entrapped, benign epithelial, and myoepithelial cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Papillary / diagnosis. Keratins / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784976.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


74. Yam J, Schaab A, Kreuter M, Drewe J: Piper cubeba demonstrates anti-estrogenic and anti-inflammatory properties. Planta Med; 2008 Feb;74(2):142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that P9605 significantly inhibited growth induced by beta-estradiol in MCF-7, a human breast cancer cell line.
  • These results support the potential use of P9605 in phytotherapy against benign prostatic hyperplasia (BPH).
  • [MeSH-minor] Arachidonate 5-Lipoxygenase / drug effects. Arachidonate 5-Lipoxygenase / metabolism. Breast Neoplasms. Cell Line, Tumor. Cyclooxygenase 1 / drug effects. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / drug effects. Cyclooxygenase 2 / metabolism. Female. Humans. Kinetics. Lignans / pharmacology. Thymidine / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219597.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Estrogen Receptor Modulators; 0 / Lignans; 0 / Piper cubeba extract; 0 / Plant Extracts; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; VC2W18DGKR / Thymidine
  •  go-up   go-down


75. Thorin-Savouré A, Tissier-Rible F, Guignat L, Pellerin A, Bertagna X, Bertherat J, Lefebvre H: Collision/composite tumors of the adrenal gland: a pitfall of scintigraphy imaging and hormone assays in the detection of adrenal metastasis. J Clin Endocrinol Metab; 2005 Aug;90(8):4924-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: In patients with a history of extraadrenal tumor, incidental discovery of an adrenal mass necessitates excluding the possibility of metastatic malignancy.
  • Detection of the malignant tissue is a difficult challenge when metastasis occurs in an adrenal adenoma, forming a collision/composite tumor.
  • PATIENTS AND RESULTS: Two patients with histories of mammary and sigmoid carcinomas, respectively, presented with adrenal mass discovered 8 and 3 yr after surgical removal of the primary tumor.
  • In the two cases, computerized tomographic scan showed that the adrenal tumor contained two components with low and high attenuation values, respectively.
  • Uptake of iodocholesterol by the adrenal tumor in case 1 and elevated plasma ACTH-stimulated 17-hydroxyprogesterone values in case 2 strongly argued for the diagnosis of primary adrenocortical tumors.
  • In both cases, histological examination of the tumor demonstrated the presence of metastatic carcinoma tissue in an adrenocortical adenoma, allowing classification of the neoplasia as a collision/composite tumor.
  • CONCLUSION: These observations show that collision/composite tumors of the adrenal gland formed by carcinoma metastasis in benign adenomas are a pitfall of iodocholesterol scintigraphy and/or plasma steroid assays to exclude the diagnosis of adrenal metastasis.
  • Conversely, computerized tomographic scan is a useful tool for the distinction between the benign and malignant tissues in adrenal collision/composite tumors.
  • [MeSH-major] Adenoma / pathology. Adenoma / radionuclide imaging. Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Gland Neoplasms / secondary. Breast Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] 19-Iodocholesterol. Adrenocorticotropic Hormone / blood. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914530.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 30461-91-7 / 19-Iodocholesterol; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


76. Shams TM, Samaka RM, Shams ME: Maspin protein expression: a special feature of papillary thyroid carcinoma. J Egypt Natl Canc Inst; 2006 Sep;18(3):274-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Mammary serine protease inhibitor (Maspin) is down regulated in breast and prostate cancers and is considered as a tumor suppressor gene.
  • On the contrary, it is over expressed in pancreatic and ovarian carcinomas and is reported to be an oncogene rather than a tumor suppressor gene.
  • The studies of maspin expression in thyroid neoplasia, the focus of this study, are limited.
  • We, therefore, carried out this work in order to detect the frequency and pattern of maspin expression in thyroid neoplasia.
  • MATERIAL & METHODS: An immunohistochemical approach was performed on 63 thyroid specimens showing different benign and malignant thyroid lesions.
  • There was no statistically significant relation between maspin positive cases and the studied clinicopathological parameters including patient's age, sex and tumor stage.
  • On the other hand, it was statistically significant as regards tumor multicentricity, vascular and lymphatic invasion, as well as lymph node metastasis.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Serpins / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Thyroid Gland / chemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671538.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


77. Tse GM, Chaiwun B, Lau KM, Scolyer R, Lee CS, Karim RZ, Putti TC, Law BK, Lui PC, Tan PH: Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol; 2007 Sep;60(9):1051-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: A large series of 461 phyllodes tumours (291 benign, 115 borderline malignant and 55 frankly malignant) were evaluated for endothelin-1 expression in both the epithelial cells and stromal cells by immunohistochemistry; results were correlated with the tumour grade.
  • RESULTS: For benign phyllodes tumours, the epithelial staining of endothelin was negative, weak, moderate and strong in 6%, 26%, 15% and 53% of cases respectively; results were 4%, 18%, 19% and 59% respectively for borderline and 6%, 18%, 6% and 70% respectively for frankly malignant tumours.
  • For the stromal staining, the negative, weak, moderate and strong staining was 32%, 19%, 18% and 31% respectively for benign phyllodes, 24%, 13%, 10% and 53% respectively for borderline and 8%, 16%, 17% and 59% respectively for frankly malignant tumours.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelin-1 / metabolism. Neoplasm Proteins / metabolism. Phyllodes Tumor / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / pathology. Epithelial Cells / metabolism. Female. Humans. Middle Aged. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):910-6 [8608483.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nature. 1988 Mar 31;332(6163):411-5 [2451132.001]
  • [Cites] FEBS Lett. 1988 Apr 25;231(2):440-4 [3282927.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):7856-61 [2542249.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] J Surg Oncol. 1990 Sep;45(1):46-51 [2166186.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1741-8 [1701822.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):141-7 [1309302.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):720-7 [9973223.001]
  • [Cites] Pathol Res Pract. 1998;194(2):97-104 [9584322.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4046-9 [1319837.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 30;375(1-3):133-8 [10443571.001]
  • [Cites] Histopathology. 1999 Aug;35(2):162-9 [10460662.001]
  • [Cites] Pathol Int. 1999 Sep;49(9):807-10 [10504552.001]
  • [Cites] Am J Clin Pathol. 2005 Apr;123(4):529-40 [15743740.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):129-38 [15863261.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Surg Oncol. 1995;4(6):309-15 [8809953.001]
  • [Cites] Histopathology. 2000 Feb;36(2):161-7 [10672062.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):51-61 [10708518.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Apr;22(4):422-31 [10745023.001]
  • [Cites] BJU Int. 2000 Apr;85 Suppl 2:45-8 [10781185.001]
  • [Cites] Eur J Immunol. 2002 Sep;32(9):2393-400 [12207323.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):21-8 [12497202.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1273-81 [12516960.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Pathol. 2003 May;200(1):59-64 [12692842.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4125-31 [14519635.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1007-13 [14559983.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2461-8 [15059899.001]
  • [Cites] Mod Pathol. 2004 Jul;17(7):827-31 [15044924.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1053-7 [15343505.001]
  • [Cites] Radiology. 1983 Feb;146(2):481-6 [6294737.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S1-4 [11078319.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:851-76 [11264479.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):734-40 [12118111.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • (PMID = 17158636.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1972415
  •  go-up   go-down


78. Dupuis C, Coard KC: A review of granular cell tumours at the University Hospital of the West Indies: 1965-2006. West Indian Med J; 2009 Mar;58(2):138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are usually benign, but as they are infrequently diagnosed preoperatively, they may be confused clinically with malignant lesions.
  • Of these, 99patients were female and 23 male, providing a male:female ratio of l to 4.3.
  • The ages ranged from 5 days to 82 years with a mean age (excluding the 2 youngest cases) of 34.4 years.
  • Lesions ranged in size from 0.2 cm to 10 cm in greatest dimension, the average size being 1.85 cm and were found in a diverse array of anatomic locations, the most common being the vulva, breast and tongue.
  • The correct clinical diagnosis was proffered preoperatively in only one case.
  • In contrast, a malignant diagnosis was suggested in 19 cases.
  • In particular lesions of the tongue accounted for fewer than expected, while lesions of the breast and vulva were considerably increased.
  • The well-recognized female predominance was also substantially higher than in other studies.
  • [MeSH-major] Granular Cell Tumor / epidemiology. Granular Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Infant, Newborn. Male. Middle Aged. Tongue Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology. West Indies / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21866599.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


79. Wei T, Geiser AG, Qian HR, Su C, Helvering LM, Kulkarini NH, Shou J, N'Cho M, Bryant HU, Onyia JE: DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids. BMC Womens Health; 2007;7:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Uterine fibroids or leiomyoma are a common benign smooth muscle tumor.
  • The tumor growth is well known to be estrogen-dependent.
  • Functional and pathway analyses of the twelve genes suggested multiple molecular mechanisms for estrogen-dependent cell survival and tumor growth.
  • [MeSH-minor] Animals. Databases, Genetic. Female. Humans. Myometrium / metabolism. Oligonucleotide Array Sequence Analysis. Rats. Signal Transduction. Tumor Cells, Cultured. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5737-44 [10582693.001]
  • [Cites] Biol Reprod. 2005 Apr;72(4):830-41 [15576828.001]
  • [Cites] Eur J Biochem. 2000 Jul;267(14):4315-24 [10880953.001]
  • [Cites] Mol Biol Cell. 2000 Jul;11(7):2283-95 [10888668.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):259-71 [11058767.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1503-9 [11076660.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39747-53 [10995752.001]
  • [Cites] Neuroreport. 2000 Nov 27;11(17):3719-23 [11117479.001]
  • [Cites] Hum Reprod Update. 2001 Jan-Feb;7(1):8-14 [11212080.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):293-8 [11214143.001]
  • [Cites] Mediators Inflamm. 2001 Oct;10(5):245-51 [11759108.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Genome Res. 2002 Mar;12(3):493-502 [11875039.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1729-36 [11932307.001]
  • [Cites] Gut. 2002 May;50(5):658-64 [11950812.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:67-73 [11966526.001]
  • [Cites] Fertil Steril. 2002 Jul;78(1):114-21 [12095500.001]
  • [Cites] Biol Reprod. 2002 Nov;67(5):1555-64 [12390888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):318-23 [12518068.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):28-33 [12519941.001]
  • [Cites] Genome Biol. 2003;4(1):R4 [12537549.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1221-7 [12649180.001]
  • [Cites] Mol Endocrinol. 2003 Apr;17(4):562-74 [12554762.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):149-59 [12825850.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(8):1037-54 [12826476.001]
  • [Cites] Mol Hum Reprod. 2003 Aug;9(8):481-90 [12837925.001]
  • [Cites] Fertil Steril. 2003 Aug;80(2):266-76 [12909484.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1844-55 [12829806.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35819-25 [12842898.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8651-67 [14612408.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):433-42 [14623541.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15206-11 [14638944.001]
  • [Cites] C R Biol. 2003 Oct-Nov;326(10-11):1075-8 [14744115.001]
  • [Cites] Bioinformatics. 2004 Mar 1;20(4):578-80 [14990455.001]
  • [Cites] Pol J Pharmacol. 2004 Jan-Feb;56(1):5-27 [15047974.001]
  • [Cites] World J Gastroenterol. 2004 Apr 1;10(7):1047-51 [15052691.001]
  • [Cites] Inflamm Res. 2004 Apr;53(4):125-32 [15060718.001]
  • [Cites] Genome Res. 2004 May;14(5):942-50 [15123590.001]
  • [Cites] Gut. 2004 Aug;53(8):1151-8 [15247185.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4756-62 [15205379.001]
  • [Cites] Fertil Steril. 2004 Sep;82(3):639-49 [15374708.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9705-25 [15509776.001]
  • [Cites] J Steroid Biochem. 1984 May;20(5):1195-200 [6328123.001]
  • [Cites] Nature. 1986 Mar 13-19;320(6058):134-9 [3754034.001]
  • [Cites] Cell. 1987 Dec 24;51(6):941-51 [3690665.001]
  • [Cites] Fertil Steril. 1989 Feb;51(2):251-6 [2492232.001]
  • [Cites] Acta Endocrinol (Copenh). 1989 Apr;120(4):466-72 [2718698.001]
  • [Cites] Am J Obstet Gynecol. 1990 Aug;163(2):545-50 [2386142.001]
  • [Cites] Receptor. 1993 Spring;3(1):17-30 [8348080.001]
  • [Cites] Eur J Biochem. 1993 Oct 1;217(1):313-8 [8223569.001]
  • [Cites] Hum Reprod. 1993 Nov;8(11):1796-806 [7507128.001]
  • [Cites] Trends Pharmacol Sci. 1994 Mar;15(3):71-6 [8184489.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5427-33 [7890657.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):1967-74 [8626866.001]
  • [Cites] Genome Res. 1996 Jul;6(7):639-45 [8796352.001]
  • [Cites] J Mol Med (Berl). 1996 Jul;74(7):347-52 [8841947.001]
  • [Cites] Gene. 1996 Sep 26;174(1):151-8 [8863742.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2484-92 [10344762.001]
  • [Cites] Biol Reprod. 2005 Feb;72(2):416-22 [15469997.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jul;28(3):235-45 [10862029.001]
  • (PMID = 17407572.001).
  • [ISSN] 1472-6874
  • [Journal-full-title] BMC women's health
  • [ISO-abbreviation] BMC Womens Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  • [Other-IDs] NLM/ PMC1852551
  •  go-up   go-down


80. Thittai AK, Galaz B, Ophir J: Axial-shear strain distributions in an elliptical inclusion model: experimental validation and in vivo examples with implications to breast tumor classification. Ultrasound Med Biol; 2010 May;36(5):814-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axial-shear strain distributions in an elliptical inclusion model: experimental validation and in vivo examples with implications to breast tumor classification.
  • We also show a few confirmatory examples of the existence of these phenomena in benign vs. malignant breast lesions in vivo.
  • Thus, it may be useful as a marker of benignity of benign breast lesions (e.g., fibroadenomas) that are generally stiff, elongated and loosely bonded to the host tissues.
  • [MeSH-major] Breast Neoplasms / physiopathology. Breast Neoplasms / ultrasonography. Elasticity Imaging Techniques / methods. Fibroadenoma / physiopathology. Fibroadenoma / ultrasonography. Image Interpretation, Computer-Assisted / methods. Mammography / methods
  • [MeSH-minor] Algorithms. Anisotropy. Computer Simulation. Elastic Modulus. Female. Humans. Image Enhancement / methods. Models, Biological. Phantoms, Imaging. Reproducibility of Results. Sensitivity and Specificity. Shear Strength

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20420971.001).
  • [ISSN] 1879-291X
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA64597; United States / NCI NIH HHS / CA / R21-CA135580
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


81. Fu Q, Yao GY, Tang XL, Chen LR, Zheng ZX: [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions]. Zhonghua Zhong Liu Za Zhi; 2007 Jan;29(1):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions].
  • OBJECTIVE: To investigate the incidence and clinicopathologic significance of MSI and LOH on 3P in breast carcinoma and its precancerous lesions, intraductal papillary adenoma and ductal carcinoma in situ.
  • METHODS: 41 paired sporadic invasive breast carcinomas, 13 archival precancerous lesion specimens of the breast and 14 couples of benign hyperplasia were collected.
  • There was no MSI in benign hyperplasia.
  • Of the 11 loci examined, D3S1295, D3S1029 and D3S1038 were identified as the locus with most frequent LOH which were all correlated significantly with some clinicopathological parameters such as histological type, lymph node metastasis in breast cancer, while D3S1295 and D3S1029 were the most frequent markers in precancerous lesions.
  • Positive expression of hMLH1 and hMSH2 protein was detected in breast carcinomas in scattered distribution and their positive rate was 45% and 40% , respectively.
  • CONCLUSION: Defective expression of MMR genes is closely associated with the development of breast cancer.
  • MSI indicates poor histological differentiation in breast carcinoma.
  • D3S1766 and D2S2739 might be the sensitive sites to detect MSI in breast carcinoma and precancerous lesions.
  • The smallest common LOH deletion regions seem likely to be situated between 3p14 and 3p25, indicating the existence of breast tumor related genes in those regions and some of them might affect tumor development.
  • [MeSH-major] Breast Neoplasms / pathology. Chromosome Deletion. Chromosomes, Human, Pair 3 / genetics. Microsatellite Instability. Precancerous Conditions / pathology
  • [MeSH-minor] Acid Anhydride Hydrolases / metabolism. Adaptor Proteins, Signal Transducing / metabolism. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. DNA Mismatch Repair. Female. Humans. Hyperplasia. Immunohistochemistry. Loss of Heterozygosity. Lymphatic Metastasis. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Nuclear Proteins / metabolism. Polymerase Chain Reaction. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575691.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


82. Tremblay G, Deschênes J, Alpert L, Quenneville LA: Overexpression of estrogen receptors in columnar cell change and in unfolding breast lobules. Breast J; 2005 Sep-Oct;11(5):326-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of estrogen receptors in columnar cell change and in unfolding breast lobules.
  • However, some investigators have suggested that it may be a marker for increased risk of breast cancer.
  • To see whether CCC is subject to hormonal influences, the distribution of estrogen receptors (ER) was determined in a series of breast specimens showing this change.
  • The cases came from 51 women age 35-80 years (mean 52 years) with the following associated findings: 27 carcinomas and 24 benign lesions.
  • It is now recognized that columnar cell lesions include a wide spectrum of changes reaching a point at the upper end where the differential diagnosis is ductal carcinoma in situ.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Cell Transformation, Neoplastic / pathology. Epithelial Cells / pathology. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Disease Progression. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174153.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen
  •  go-up   go-down


83. Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, Semmes OJ, Perry RR, Drake RR: Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg; 2007 May;204(5):1065-71; discussion 1071-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum biomarkers to differentiate benign and malignant mammographic lesions.
  • BACKGROUND: Mammographic screening has increased detection of earlier-stage breast cancers and has decreased mortality from breast cancer.
  • A Breast Imaging-Reporting and Data System (BIRADS) 4 classification prompts a biopsy that most often reveals benign disease.
  • Our objective was to determine if serum protein-expression profiles could be used to differentiate between benign and malignant mammographic lesions.
  • Sera from 92 subjects were randomly selected to form benign (n = 46) and cancer (n = 46) cohorts.
  • The MALDI-TOF spectra analysis yielded 273 peaks, with 14 peaks expressed differentially (p < 0.05) between the cancer and benign cohorts.
  • CONCLUSIONS: MALDI-TOF protein-expression profiles generated from BIRADS 4 sera could be used to distinguish between benign and malignant mammographic lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481542.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA98028
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


84. Schem Ch, Bauerschlag DO, Meinhold-Heerlein I, Fischer D, Friedrich M, Maass N: [Benign and borderline tumors of the ovary]. Ther Umsch; 2007 Jul;64(7):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign and borderline tumors of the ovary].
  • [Transliterated title] Benigne und Borderline-Tumoren des Ovars.
  • Although diagnostic procedures might be supplemented by CT-Scan or MRI techniques, classical bimanual examination and vaginal ultrasound scan will determine the diagnosis in most cases comparably accurate.
  • The suspected diagnosis concerning benign or malignant lesions, should take the palpable and sonographic feature, as well as the information from the patients medical history (e.g. family history of malignant diseases (BRCA 1/2 mutations) into account.
  • They are mostly normal follicle cysts, but may also be a tumor of low malignant potential (LMP-tumor) or even an invasive cancerous lesion.
  • 20-30% of all ovarian tumors are malignant and by the time of primary diagnosis already in a about 60-70% incurable due to intraabdominal dissemination.
  • Benign or malignant lesions may occur in every age group.
  • Hormonal contraceptives, pregnancy and breast feeding seem to be protective.
  • In that respect the diagnosis of LMP-tumors might be incidentally and will then have a substantial impact on the extent of the surgery and the follow up.
  • This compilation overviews the spectrum of benign and low malignant potential tumors of the ovary and their different tissues of origin.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Ovarian Cysts / diagnosis. Ovarian Cysts / radiography. Ovarian Cysts / ultrasonography. Ovary / pathology. Palpation. Time Factors. Tomography, X-Ray Computed. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948753.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 22
  •  go-up   go-down


85. Abdalla HM, Sakr MA: Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast. J Egypt Natl Canc Inst; 2006 Jun;18(2):125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast.
  • BACKGROUND AND PURPOSE: The phyllodes tumor is characterized by its tendency to recur locally and occasionally to metastasize.
  • The aim of this study was to determine parameters that influence outcome in this uncommon neoplasm.
  • The tumor size ranged from 2.5 to 24 cm, with a median of 11 cm.
  • Based on the criteria proposed by WHO, 31 cases were benign tumors (39.2%), 27 borderline tumors (34.2%), and 21 malignant tumors (26.6%).
  • Following local excision, the local recurrence rates were 14.3%, 50%, and 75% in patients with benign, borderline, and malignant tumors; respectively, while after wide local excision the local recurrence rates were 0%, 36.3% and 40%; respectively.
  • Whereas, 0%, 8.3%, and 8.3% of patients with benign, borderline and malignant tumors; respectively, locally recurred after mastectomy.
  • Distant metastases developed in 3.2%, 11.1%, and in 28.6% of patients with benign, borderline and malignant tumors; respectively.
  • The 5-year survival with no evidence of disease was 90% for the patients with benign tumors compared to 69% for borderline and 61% for malignant PTs (p= 0.02).
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Phyllodes Tumor / pathology
  • [MeSH-minor] Adolescent. Aged. Female. Humans. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496937.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


86. Wu K, Quan Z, Weng Z, Li F, Zhang Y, Yao X, Chen Y, Budman D, Goldberg ID, Shi YE: Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treat; 2007 Mar;101(3):259-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
  • However, synuclein gamma (SNCG), previously identified as a breast cancer specific gene (BCSG1), is also highly expressed in breast carcinomas, but not expressed in normal or benign breast tissues.
  • We analyzed SNCG gene expression in 93 clinical breast specimens and associated it with clinical outcome.
  • Overall SNCG mRNA expression was detectable in 36% breast cancers.
  • However, 81% of stage III/IV breast cancers were positive for SNCG expression, while only 15% of stage I/II breast cancers were positive for SNCG expression.
  • In contrast, SNCG was undetectable in benign breast lesions.
  • Expression of SNCG in the primary tumor also significantly associated with lymph node involvement and metastasis.
  • This study suggests that the expression of SNCG is an independent predictive marker for recurrence and metastasis in breast cancer progression.
  • SNCG is expected to be a useful marker for breast cancer progression and a potential target for breast cancer treatment.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Neoplasm Proteins / genetics. gamma-Synuclein / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / secondary. Disease Progression. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Middle Aged. Neoplasm Staging. Neoplasms / genetics. Neoplasms / metabolism. Neoplasms / pathology. Prognosis. RNA, Messenger / analysis. Retrospective Studies


87. Ohsie SJ, Moatamed NA, Chang HR, Apple SK: Heterotopic breast tissue versus occult metastatic carcinoma in lymph node, a diagnostic dilemma. Ann Diagn Pathol; 2010 Aug;14(4):260-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterotopic breast tissue versus occult metastatic carcinoma in lymph node, a diagnostic dilemma.
  • Breast cancer is the leading cause of cancer in women and the third leading cause of cancer mortality in the United States.
  • We report a case of a patient who underwent bilateral simple mastectomies and right sentinel node biopsy for invasive lobular carcinoma in the right breast.
  • Although residual lobular carcinoma was identified in the right breast, no ductal carcinoma was identified in either breast.
  • The differential diagnosis includes heterotopic epithelial inclusions and benign mechanical transport.
  • Mechanical transport of the breast tissue was ruled out because primary tumor type in the breast and the ductal structures in the lymph nodes were of different types.
  • The diagnosis of occult metastatic tumor was based on the lack of the myoepithelial layers associated with the ductal structures.
  • [MeSH-major] Breast. Carcinoma, Ductal, Breast / secondary. Choristoma. Lymph Nodes / pathology. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20637431.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Egormin PA, Yurova MV, Rosenfeld SV, Semenchenko AV, Kovalenko IG, Poroshina TE, Berstein LM: Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY); 2010 Dec;2(12):945-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chronic treatment of inbred 129/Sv mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but failed to influence the dynamics of body weight, decreased by 13.4% the mean life span of male mice and slightly increased the mean life span of female mice (by 4.4%).
  • The treatment with metformin failed influence spontaneous tumor incidence in male 129/Sv mice, decreased by 3.5 times the incidence of malignant neoplasms in female mice while somewhat stimulated formation of benign vascular tumors in the latter.
  • [MeSH-minor] Age Factors. Animals. Blood Glucose / metabolism. Body Temperature / drug effects. Body Weight / drug effects. Cholesterol / blood. Chromosome Aberrations / chemically induced. Drinking / drug effects. Eating / drug effects. Estrus / drug effects. Female. Insulin / blood. Male. Mice. Mice, 129 Strain. Sex Factors. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Novartis Found Symp. 2002;242:222-42; discussion 242-6 [11855690.001]
  • [Cites] Methods Mol Biol. 2007;371:227-36 [17634585.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):385-91 [11927499.001]
  • [Cites] Diabetes Metab Res Rev. 2002 Mar-Apr;18(2):156-9 [11994908.001]
  • [Cites] Biochem J. 2008 Jun 1;412(2):211-21 [18387000.001]
  • [Cites] Drugs Today (Barc). 2008 Apr;44(4):303-14 [18536788.001]
  • [Cites] Cell Cycle. 2008 Sep 1;7(17):2769-73 [18728386.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1520-4 [18769112.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jan;113(1):101-11 [18256928.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):909-15 [19221498.001]
  • [Cites] Science. 2009 Jul 10;325(5937):201-4 [19590001.001]
  • [Cites] Nature. 2009 Jul 16;460(7253):392-5 [19587680.001]
  • [Cites] J Pathol. 2009 Sep;219(1):35-40 [19434632.001]
  • [Cites] Science. 2009 Oct 2;326(5949):140-4 [19797661.001]
  • [Cites] Cell Cycle. 2010 Jan 1;9(1):188-97 [20016287.001]
  • [Cites] PLoS One. 2010;5(1):e8758 [20090912.001]
  • [Cites] Aging (Albany NY). 2009 Mar;1(3):281-8 [20157517.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2010 May;65(5):468-74 [20304770.001]
  • [Cites] Science. 2010 Apr 16;328(5976):321-6 [20395504.001]
  • [Cites] Am J Pathol. 2010 May;176(5):2092-7 [20363920.001]
  • [Cites] BMJ. 2010;340:c2198 [20488912.001]
  • [Cites] Ageing Res Rev. 2010 Jul;9(3):324-53 [19853062.001]
  • [Cites] Future Oncol. 2010 Aug;6(8):1313-23 [20799876.001]
  • [Cites] Vopr Onkol. 2010;56(5):583-7 [21137239.001]
  • [Cites] Aging (Albany NY). 2010 Nov;2(11):760-74 [21084729.001]
  • [Cites] Am J Med Sci. 2002 Mar;323(3):140-5 [11908858.001]
  • [Cites] Free Radic Biol Med. 2000 Dec 15;29(12):1302-6 [11118820.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1263-70 [11266389.001]
  • [Cites] J Clin Invest. 2001 Oct;108(8):1167-74 [11602624.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Mar;56 Spec No 1:5-6 [12088212.001]
  • [Cites] J Obstet Gynaecol Can. 2002 May;24(5):393-401 [12196859.001]
  • [Cites] Genes Dev. 2003 Feb 1;17(3):313-21 [12569120.001]
  • [Cites] Biogerontology. 2003;4(1):1-8 [12652183.001]
  • [Cites] Biogerontology. 2003;4(5):297-307 [14618027.001]
  • [Cites] Life Sci. 2003 Dec 19;74(5):643-50 [14623034.001]
  • [Cites] Med J Aust. 2004 Jan 19;180(2):53-4 [14723582.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):505-18 [15229476.001]
  • [Cites] Vopr Onkol. 1980;26(6):42-8 [7189923.001]
  • [Cites] Gerontology. 1980;26(5):241-6 [7390164.001]
  • [Cites] Drug Saf. 1994 Oct;11(4):223-41 [7848543.001]
  • [Cites] Diabetes Care. 1999 Jan;22(1):179-80 [10333929.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):1117-29 [15743682.001]
  • [Cites] Cancer Lett. 2005 Jun 28;224(2):203-12 [15914271.001]
  • [Cites] Exp Gerontol. 2005 Aug-Sep;40(8-9):685-93 [16125352.001]
  • [Cites] Science. 2005 Dec 9;310(5754):1642-6 [16308421.001]
  • [Cites] Aging Cell. 2006 Apr;5(2):97-108 [16626389.001]
  • [Cites] Cell Cycle. 2006 Sep;5(18):2087-102 [17012837.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10269-73 [17062558.001]
  • [Cites] Neurosci Lett. 2007 Jan 10;411(2):98-103 [17110029.001]
  • [Cites] Drug Discov Today. 2007 Mar;12(5-6):218-24 [17331886.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [CommentIn] Aging (Albany NY). 2010 Dec;2(12):897-9 [21212463.001]
  • (PMID = 21164223.001).
  • [ISSN] 1945-4589
  • [Journal-full-title] Aging
  • [ISO-abbreviation] Aging (Albany NY)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Triglycerides; 9100L32L2N / Metformin; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC3034183
  •  go-up   go-down


89. Chen L, Madura K: Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res; 2005 Jul 1;65(13):5599-606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
  • The activation of this pathway in various cancers and malignancies has been described, and several genetic determinants of breast cancer, including BRCA1 and BRCA2, are linked to protein degradation.
  • To investigate the involvement of the Ub/proteasome system in breast cancer, we examined a collection of 25 patient-matched breast cancer and normal adjacent tissues and detected activation of numerous components of the Ub/proteasome pathway.
  • The activity of the proteasome, and levels of proteasome subunits and various targeting factors, were increased in >90% of primary breast cancer tissue specimens.
  • In contrast, no activation was observed in benign solid tumors, indicating that the response is specific to abnormal growth in neoplastic cells.
  • Additionally, the accumulation of high levels of certain Ub-conjugating enzymes (UbcH1, UbcH2, and UbcH5), was specific to breast cancer, as no change in abundance was detected in primary colon cancer tissue extracts.
  • Surprisingly, the Ub/proteasome system was not activated in a well-characterized cell culture-based breast cancer model system.
  • Collectively, these findings suggest that the analysis of primary breast cancer tissue samples will be indispensable for the biochemical characterization of neoplastic growth and for the development of therapeutics.
  • [MeSH-major] Breast Neoplasms / enzymology. Peptide Elongation Factor 1 / metabolism. Proteasome Endopeptidase Complex / metabolism. Ubiquitin-Conjugating Enzymes / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured. Ubiquitin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994932.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83875
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Elongation Factor 1; 0 / Ubiquitin; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  •  go-up   go-down


90. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A: Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol; 2007 Jan;35(1):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
  • [MeSH-major] Artifacts. Ascitic Fluid / pathology. Cytodiagnosis / methods. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Specimen Handling / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


91. Azab SS, Salama SA, Hassan MH, Khalifa AE, El-Demerdash E, Fouad H, Al-Hendy A, Abdel-Naim AB: 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft. Cancer Chemother Pharmacol; 2008 Oct;62(5):893-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft.
  • This study was designed to investigate the modulatory effect of 2ME on the antitumor effect of doxorubicin (Dox) in resistant breast tumor xenograft.
  • RESULTS: Following 28 days from starting the treatment with Dox alone, the change in tumor volume from first day of treatment was 455.6 +/- 16.2%.
  • Combined Dox and 2ME treatment significantly reduced tumor volume to 20.8 +/- 43%.
  • Also, combined therapy resulted in enhanced tumor apoptotic and reduced proliferative activities relative to Dox alone.
  • CONCLUSION: These findings suggest that 2ME reverses Dox resistance, with benign side effects profile.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Breast Neoplasms / drug therapy. Doxorubicin / pharmacology. Drug Resistance, Neoplasm / drug effects. Estradiol / analogs & derivatives
  • [MeSH-minor] Algorithms. Angiogenesis Inhibitors / pharmacology. Animals. Apoptosis / drug effects. Body Weight / drug effects. Cell Proliferation / drug effects. Drug Synergism. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Liver / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Myocardium / pathology. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18253735.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibiotics, Antineoplastic; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol; 80168379AG / Doxorubicin
  •  go-up   go-down


92. Ding Y, Ruan Q: The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J Huazhong Univ Sci Technolog Med Sci; 2006;26(4):405-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
  • In order to explore the value of p63, smoothmuscle actin (alpha-SMA) and cytokeratin 5/6 (CK5/6) in the differential diagnosis of ductal lesions of breast, 88 tissue specimens of ductal lesions of breast were collected and examined histologically by HE staining.
  • The results showed that in 38 cases of benign breast lesions, the proliferating cells were all positive for p63 and alpha-SMA.
  • In 38 cases of benign breast lesions, the positive rate of CK5/6 expression was 100%.
  • In 19 cases of CDIS, no tumor cells expressed CK5/6.
  • It was suggested that p63 could serve as a novel specific marker for the identification of breast myoepithelial cells.
  • Simultaneous detection of p63, CK5/6 and alpha-SMA can help increase the diagnostic accuracy of breast diseases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis
  • [MeSH-minor] Breast Diseases / diagnosis. Breast Diseases / metabolism. Diagnosis, Differential. Female. Fibrocystic Breast Disease / diagnosis. Humans. Immunohistochemistry. Papilloma, Intraductal / diagnosis. Papilloma, Intraductal / metabolism. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2002 Apr;15(4):397-405 [11950913.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):548-54 [12712335.001]
  • [Cites] Histopathology. 2005 Aug;47(2):202-8 [16045782.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):82-90 [12502930.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] In Vivo. 2003 Nov-Dec;17(6):573-6 [14758723.001]
  • (PMID = 17120733.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins
  •  go-up   go-down


93. Nields MW: Industry perspective: maximizing the benefit of improved detection with guided and monitored thermal ablation of small tumors. Technol Cancer Res Treat; 2005 Apr;4(2):123-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The continuous growth of mammography is driven by global acceptance of the demonstrated ability of screening mammography to reduce mortality from breast cancer.
  • An increasing number of benign and malignant tumors are being diagnosed as a result of the growth in mammography, improvements in technology, especially digital mammography, as well as by an increase in patient surveillance.
  • Breast imaging technology for cancer screening continues to improve, with the integration of ultrasound with digital mammography showing promise that an even larger number of small abnormalities will be detected in screening programs.
  • The results of minimally invasive ablative techniques as tested in pilot clinical studies for breast tumor ablation are reviewed.
  • An improved ability to intraoperatively monitor thermal ablative methods may enable more accurate minimally invasive treatment of an ever increasing number of both benign and malignant breast tumors.
  • [MeSH-major] Breast Neoplasms / surgery. Catheter Ablation / trends. Minimally Invasive Surgical Procedures / trends
  • [MeSH-minor] Female. Hot Temperature. Humans. Mammography. Mass Screening

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773781.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


94. Losken A, Styblo TM, Carlson GW, Jones GE, Amerson BJ: Management algorithm and outcome evaluation of partial mastectomy defects treated using reduction or mastopexy techniques. Ann Plast Surg; 2007 Sep;59(3):235-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this series was to try to create a treatment algorithm based on patient selection, diagnosis, margins, and recurrence in an attempt to maintain oncologic safety, as well as to improve esthetic outcome.
  • Histology was invasive carcinoma (n = 33), ductal carcinoma in situ (DCIS) (n = 20), fibroadenoma (n = 6), and benign breast tissue (n = 4).
  • The most common tumor location was upper outer quadrant, and the various pedicles used were superomedial (n = 22), inferior (n = 20), central (n = 7), and other (n = 14).
  • Total specimen weight on the tumor side was 762 g and 858 g on the contralateral side, to accommodate for radiation fibrosis.
  • In patients with breast cancer (n = 53), 26% required either fine needle aspiration or excisional biopsy for cancer surveillance postoperatively.
  • All 4 patients who failed the combined approach were younger women with the diagnosis of extensive DCIS.
  • Versatility exists using various pedicles and skin patterns to reconstruct all breast shapes and defect locations.
  • [MeSH-major] Breast Neoplasms / surgery. Mammaplasty. Mastectomy, Segmental / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Child. Female. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Plast Surg. 2007 Nov;59(5):592; author reply 593 [17992158.001]
  • (PMID = 17721207.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Huang KT, Dobrovic A, Yan M, Karim RZ, Lee CS, Lakhani SR, Fox SB: DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Res Treat; 2010 Nov;124(2):555-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast.
  • Phyllodes tumours and cellular fibroadenomas are both fibroepithelial tumours of the breast.
  • Although these lesions can be distinguished by their stromal cellularity, mitotic index, presence or absence of stromal overgrowth and cellular atypia, there is overlap and not infrequently a definitive diagnosis cannot be made, particularly on biopsy.
  • Methylation-sensitive high resolution melting (MS-HRM) was used to screen promoter DNA methylation changes in 86 phyllodes tumours (15 benign, 28 borderline, 43 malignant) and 26 fibroadenomas.
  • In conclusion, assessment of methylation of RASSF1A and TWIST1 may aid in the diagnosis of phyllodes tumours.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. DNA Methylation. Fibroadenoma / genetics. Gene Expression Profiling. Genetic Markers. Phyllodes Tumor / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Australia. Chi-Square Distribution. Female. Humans. Logistic Models. Middle Aged. Nuclear Proteins / genetics. Promoter Regions, Genetic. Risk Assessment. Risk Factors. Tumor Suppressor Proteins / genetics. Twist Transcription Factor / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20563638.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / TWIST1 protein, human; 0 / Tumor Suppressor Proteins; 0 / Twist Transcription Factor
  •  go-up   go-down


96. Odashiro M, Lima MG, Miiji LN, Odashiro DN, Carvalho GV, Prates Campos JC, Odashiro AN: Infiltrating syringomatous adenoma of the nipple. Breast J; 2009 Jul-Aug;15(4):414-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infiltrating syringomatous adenoma of the nipple is a rare, benign, locally invasive tumor with recurrence potential, showing sweat duct differentiation.
  • The lesion was surgically removed and histopathologically, the tumor was composed of ducts and tubules lined with a double-layered epithelial cells.
  • [MeSH-major] Adenoma / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Nipples / pathology. Syringoma / surgery
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470133.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Garg S, Mohan H, Bal A, Attri AK, Kochhar S: A comparative analysis of core needle biopsy and fine-needle aspiration cytology in the evaluation of palpable and mammographically detected suspicious breast lesions. Diagn Cytopathol; 2007 Nov;35(11):681-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative analysis of core needle biopsy and fine-needle aspiration cytology in the evaluation of palpable and mammographically detected suspicious breast lesions.
  • The present study was undertaken to compare the efficacy of needle core biopsy (NCB) of the breast with fine-needle aspiration cytology (FNAC) in breast lesions (palpable and non-palpable) in the Indian set-up, along with the assessment of tumor grading with both the techniques.
  • Fifty patients with suspicious breast lesions were subjected to simultaneous FNAC and ultrasound-guided NCB following an initial mammographic evaluation.
  • Cases were categorized into benign, benign with atypia, suspicious and malignant groups.
  • Out of 50 cases, 18 were found to be benign and 32 malignant on final pathological diagnosis.
  • Maximum number of patients with benign diagnosis was in the fourth decade (42.11%) and malignant diagnosis in the fourth as well as fifth decade (35.48% each).
  • Sensitivity and specificity of mammography for the diagnosis of malignancy was 84.37% and 83.33%, respectively.
  • Sensitivity and specificity of FNAC for malignant diagnosis was 78.15% and 94.44%, respectively, and of NCB was 96.5% and 100%, respectively.
  • Tumor grading in cases of IDC showed high concordance rate between NCB and subsequent excision biopsy (94.44%) but low concordance rate between NCB and FNAC (59.1%).
  • NCB is superior to FNAC in the diagnosis of breast lesions in terms of sensitivity, specificity, correct histological categorization of the lesions as well as tumor grading.
  • [MeSH-major] Biopsy, Fine-Needle. Biopsy, Needle. Breast / pathology. Breast Diseases / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Mammography. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17924407.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Li JR, Li MQ, Li JZ: [Diagnosis and treatment of breast lumps in children]. Zhonghua Yi Xue Za Zhi; 2008 Sep 23;88(36):2556-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of breast lumps in children].
  • OBJECTIVE: To summarize the diagnosis and treatment of breast lumps in children.
  • METHODS: The clinical data of 61 children with breast lumps, 20 with physiological breast masses, 5 male and 15 female, aged 1 - 14, 38 with benign tumors, 1 male and 37 female, aged 10 - 14, 3 with malignant tumors, aged 7 months, and 10 and 13 years. diagnosed and treated 2001 - 2006 were analyzed.
  • The 38 cases with benign tumors all underwent resection, 36 cases were cured and 2 cases recurred.
  • Recurrence was not seen in 2 of the 3 cases of malignant breast tumors, and the patient of leiomyosarcoma died one year after the operation.
  • CONCLUSION: Physiological breast masses in children needn't treatment; mostly enjoy spontaneous cure.
  • The outcomes of benign breast tumors in children are good after operation.
  • Malignant breast tumor is rare, and it is still difficult to predict its prognosis now.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / surgery
  • [MeSH-minor] Adolescent. Breast Diseases / diagnosis. Breast Diseases / surgery. Child. Child, Preschool. Female. Humans. Infant. Male. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080650.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Jordan SJ, Green AC, Whiteman DC, Webb PM: Risk factors for benign serous and mucinous epithelial ovarian tumors. Obstet Gynecol; 2007 Mar;109(3):647-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign serous and mucinous epithelial ovarian tumors.
  • OBJECTIVE: To investigate the risk factors for benign serous and mucinous epithelial ovarian tumors.
  • METHODS: Cases were women newly diagnosed with benign serous ovarian tumors (n=230) or benign mucinous tumors (n=133) between 2002 and 2005.
  • RESULTS: Current smoking was associated with a three-fold increase in risk of benign mucinous tumors (OR 3.25, 95% CI 1.97-5.34), and there was a trend of increasing risk with increasing amount smoked (P<.001).
  • Both recent obesity (OR 1.93, 95% CI 1.30-2.88) and obesity at age 20 (OR 4.38, 95% CI 1.88-10.20) were associated with increased risk of benign serous ovarian tumors, and having had a hysterectomy was also related to increased risk of serous (OR 2.75, 95% CI 1.90-3.96), but not mucinous tumors.
  • Ever having had a term pregnancy was inversely associated with both tumor types (combined OR 0.65, 95% CI 0.43-0.97), although greater numbers of pregnancies did not decrease risk further.
  • CONCLUSION: Our results suggest some differences in risk factors between benign serous and mucinous epithelial ovarian tumors and that risk factors for benign serous tumors differ from those well established for ovarian cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Feeding / statistics & numerical data. Estrogen Replacement Therapy. Female. Humans. Hysterectomy / statistics & numerical data. Life Style. Logistic Models. Middle Aged. Odds Ratio. Parity. Pregnancy. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329516.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


100. Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH: Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. Int J Biol Markers; 2009 Jul-Sep;24(3):130-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.
  • AIM: Novel diagnostic breast cancer markers have been extensively searched for in the proteome, using, among others, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS).
  • MATERIAL AND METHODS: We investigated breast cancer (n=75) and control (n=26) serum and tissue samples, collected prospectively by rigorous adherence to a strictly defined protocol.
  • RESULTS: Three serum peaks were significantly associated with breast cancer, while in tissue, 27 discriminative peaks were detected.
  • Several peak clusters gradually increased or decreased in intensity from healthy to benign to cancer, or with increasing cancer stage.
  • These are likely to have been generated by (breast) cancer-specific proteolytic activity in the tumor microenvironment.
  • CONCLUSIONS: These albumin fragment scan potentially provide insights into the pathophysiological mechanisms associated with, or underlying, breast cancer, and aid in improving breast cancer diagnosis.
  • [MeSH-major] Blood Proteins / analysis. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Aged. Diagnosis-Related Groups. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787623.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down






Advertisement